<PAGE>
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1998
[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number 0-19386
FISCHER IMAGING CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 36-2756787
(State of incorporation) (I.R.S. Employer Identification No.)
12300 North Grant Street
Denver, Colorado 80241
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (303) 452-6800
Securities Registered Pursuant to Section 12(b) of the Act: None
Securities Registered Pursuant To Section 12(g) of the Act:
Common Stock, Par Value $0.01
Per Share
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.. Yes [X] No [_]
[_] Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to
the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K.
The aggregate market value of the common equity held by non-affiliates of
the Registrant as of March 1, 1999 was approximately $10,789,000.
The number of shares of Registrant's Common Stock outstanding on March 1,
1999 was 7,029,000.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Registrant's Proxy Statement for its 1999 Annual Meeting of
Stockholders to be filed on or prior to April 30, 1999, are incorporated by
reference into Part III of this Form 10-K.
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
<PAGE>
FISCHER IMAGING CORPORATION
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
Part I
<C> <S> <C>
Item 1. Business...................................................... 1
Item 2. Properties.................................................... 21
Item 3. Legal Proceedings............................................. 21
Item 4. Submission of Matters to a Vote of Security Holders........... 21
Part II
Item 5. Market for Registrant's Common Equity and Related Stockholder 22
Matters......................................................
Item 6. Selected Consolidated Financial Data.......................... 25
Item 7. Management's Discussion and Analysis of Financial Condition 26
and Results of Operations....................................
Item 8. Financial Statements and Supplementary Data................... F-1
Item 9. Changes in and Disagreements with Accountants on Accounting 36
and Financial Disclosure.....................................
Part III
Item 10. Directors and Executive Officers of the Registrant............ 37
Item 11. Executive Compensation........................................ 37
Item 12. Security Ownership of Certain Beneficial Owners and 37
Management...................................................
Item 13. Certain Relationships and Related Transactions................ 37
Part IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 38
8-K..........................................................
Signatures.................................................... 40
</TABLE>
<PAGE>
PART I
ITEM 1. BUSINESS
Fischer Imaging Corporation, incorporated in the State of Delaware in 1991,
designs, manufactures and markets specialty and general purpose medical
imaging systems for diagnosing and treating disease. The company's newer
products are directed towards medical specialties, such as diagnosing and
treating breast cancer, heart disease and vascular disease, in which image-
guided, minimally invasive therapies are replacing open surgical procedures.
The company also designs and manufactures specialty x-ray imaging components
and subsystems for several leading medical products companies as an Original
Equipment Manufacturer ("OEM") and sells general radiology systems for use in
hospitals, clinics and physicians' offices.
Products and Markets
The company's proprietary products serve major markets including: Breast
Cancer Screening and Biopsy, Electrophysiology, Endovascular and
Interventional, and General Radiology.
As an OEM, the company designs and manufactures specialty x-ray imaging
components and subsystems for several leading medical equipment manufacturers
including the GE Medical Systems division of General Electric Company, Varian
Associates, Inc., and Picker International, Inc.
Breast Cancer Imaging and Biopsy Markets
Market Overview
Breast cancer is the leading cause of death from cancer in the United States
among the 27 million women between the ages of 40 and 55 and the second
leading cause of death from cancer among all women. According to the American
Cancer Society, each year about 180,000 new cases of breast cancer are
diagnosed and 43,000 women die from the disease. The incidence of breast
cancer increases with age, rising from about 100 cases per 100,000 women at
age 40 to about 400 cases per 100,000 women at age 65. Thus, the company
believes that the significant aging of the population, combined with improved
education and awareness of breast cancer and diagnostic methods, will lead to
an increased number of breast cancer screening and diagnostic procedures.
Successful treatment of breast cancer is largely dependent on early
detection of malignant lesions. According to the National Cancer Institute,
the five-year survival rate decreases from about 90% to 70% after the cancer
has spread to the lymph nodes, and to less than 20% after it has spread to
organs such as the lungs, liver, or brain. Current methods of detecting breast
cancer typically include clinical and self-examination and conventional x-ray
screening mammography. While these methods can indicate the presence of
lesions, they cannot indicate whether the lesions are benign or malignant. If
an examination or screening mammogram detects a suspicious lesion, or if other
breast cancer symptoms are present, additional diagnostic mammography is
typically ordered.
When the results of a diagnostic mammogram are inconclusive, a breast biopsy
is typically performed. The company believes that about one million biopsies
are performed each year, 70% to 90% of which result in a benign diagnosis. The
most common forms of biopsy are: (i) open surgical, (ii) stereotactic core
needle and (iii) ultrasound-guided core needle biopsies.
Open Surgical Biopsy. Open surgical biopsy has been the most commonly used
method of diagnosing breast cancer for many years. An important advantage of
open surgical biopsy is that a sufficient tissue sample necessary for
definitive diagnosis is usually obtained. However, the procedure has several
disadvantages:
. it typically must be performed in an operating room under general
anesthesia,
. the surgery takes about one hour and requires one to two days of
recuperation at home,
1
<PAGE>
. the skin incision and the large amount of tissue removed may be
disfiguring,
. internal scar tissue can interfere with the ability to detect suspicious
lesions during subsequent mammograms, and
. including surgical fees and operating room costs, the cost per procedure
is believed to be about $2,500 to $5,000.
Stereotactic Core Needle Biopsy. "Stereotactic" refers to the technique of
locating a lesion in a three-dimensional field and directing the tip of a core
needle to the site of the lesion for tissue removal and biopsy. Pioneered by
the company and several radiologists in the late 1980's, stereotactic core
needle biopsy is a less-invasive, lower cost, and less disfiguring alternative
to open surgery. Stereotactic core needle biopsies using systems such as the
company's Mammotest system can be performed in a physician's office, breast
imaging center, or hospital. Initially performed primarily by radiologists,
the procedure is now being widely adopted by surgeons as they become aware of
the accuracy and less-invasive nature of the procedure. The typical cost for
the procedure is believed to be about $750 to $1,200.
During a stereotactic core needle biopsy procedure, the patient lies face
down in a prone position on an x-ray imaging table with the breast extending
through an opening in the table. The x-ray imaging system and the doctor's
work space is under the table. The physician is able to locate the lesion in a
three-dimensional field and accurately position the core needle to within one
millimeter for tissue sample removal. The patient is given a local anesthetic
during the less than one hour procedure, and a small nick is made in the
patient's skin which, at the conclusion of the procedure, can be covered with
a band-aid. As with open surgical biopsy, the tissue sample is sent to a
pathology laboratory for analysis.
The company believes that the number of stereotactic core needle biopsy
procedures has grown from about 500 per year in 1990 to, in recent years, over
200,000 per year. This increase is believed to be driven by the clinical and
cost advantages, as well as improvements in tissue removal systems (such the
Mammotome(TM) device from Biopsys Medical, Inc., a Johnson & Johnson company,
which can be used in conjunction with the company's Mammotest system).
Television programs in recent years which discuss the benefits of stereotactic
core needle biopsy have increased awareness both among women and among managed
care organizations as to the cost savings and less-invasive nature of the
procedure. The company believes that another factor causing an increase in the
number of biopsies requested, including stereotactic, is the fact that the
leading cause of malpractice lawsuits against physicians is the failure to
detect breast cancer on a timely basis.
Ultrasound-Guided Core Needle Biopsy. Ultrasound imaging can play an
important supporting role to mammography due to its ability to diagnose cysts
and to properly characterize masses. An additional advantage is that the
patient is not exposed to x-ray radiation. The quality of ultrasound equipment
has only recently improved to the level needed for breast imaging and, as yet,
those who perform mammograms are typically not trained in breast ultrasound
imaging techniques. Nonetheless, the company believes that the capability of
ultrasound to permit the identification of some breast masses without exposing
the patient to x-ray radiation may result in increased use of ultrasound for
diagnosis of breast masses and for core needle biopsies in the future.
Other Technologies In Development. Other developing technologies that may be
used to detect, diagnose, and enhance future post-diagnostic treatment of
breast cancer include digital mammography and magnetic resonance imaging. The
company has products under development using both of these technologies:
Digital Mammography. Digital mammography provides a number of advantages
over conventional x-ray mammography:
. With digital mammography, the image is displayed on a computer monitor,
which allows image contrast to be varied. This can allow a mammogram
image to be adjusted, so that it can be interpreted appropriately without
subjecting the patient to a second mammogram. Because younger women
typically have denser breast tissue, this feature may be particularly
useful in screening women under age 50.
2
<PAGE>
. A properly designed digital mammography system can reduce radiation
dosage by at least a factor of two.
. Other benefits include: (i) real time acquisition (film processing is not
necessary), (ii) storage of the mammogram in digital memory or on digital
archival media, (iii) computer-aided diagnosis, and (iv) telemammography
(digital transmission of mammograms for remote display and diagnosis).
Magnetic Resonance Imaging. Breast magnetic resonance imaging ("Breast MR"),
performed with the injection of a contrast agent, has been demonstrated in
clinical research to be more effective than film screen mammography or
ultrasound at detecting lesions and determining the extent of known breast
cancer. However, Breast MR, while more sensitive than other imaging
techniques, is no more specific than conventional x-ray mammography.
Therefore, the capability to perform core needle biopsy using MR guidance is
currently needed.
The company believes that Breast MR with biopsy capabilities will be used
primarily to provide physicians and patients with additional information
concerning the appropriateness of lumpectomy (removal of a breast tumor and
surrounding tissue) as opposed to mastectomy (removal of the entire breast).
It may also be used as an diagnostic alternative to partial mastectomy or
lumpectomy, for patients with a high risk of cancer recurrence or in other
special cases where breast cancer may be suspected but where film screen
mammography and ultrasound produce negative findings.
Products
The company serves the mammography market with stereotactic core needle
biopsy products and screening and diagnostic mammography systems.
Mammotest(R)/Mammovision(R). First introduced in 1989, the company's
Mammotest stereotactic core needle biopsy system is designed expressly for
core needle biopsy of the breast. The Mammotest system consists of an
elevating, prone position table, a mammographic x-ray imaging system and a
stereotactic needle guidance system. The company is one of only two
manufacturers worldwide of prone position tables. In 1992, the company
introduced Mammovision, the first charge coupled device ("CCD") imaging system
cleared by the U.S. Food and Drug Administration that produces breast tissue
images on nearly a real time basis. With the aid of proprietary software, the
coordinates of a breast lesion can be quickly calculated using a computer
trackball. These coordinates are then transmitted to the Autoguide, a motor-
driven needle holder assembly that precisely aims the biopsy needle at the
lesion. Mammovision has become a standard for providing computer-based imaging
for the Mammotest system.
Since 1990, over 800 Mammotest systems have been installed worldwide, with
the vast majority of installations occurring in the United States.
Mammotest Plus(TM)/Mammovision Plus(TM). The company introduced Mammotest
Plus(TM) and Mammovision Plus in November 1995. The Mammotest Plus system
permits 360 degree access to the breast. It also incorporates the features of
Target on Scout(TM) and Lateral Arm that allow small breasts (less than 2.5cm
when compressed) and breast lesions in difficult locations to be biopsied more
easily.
Mammovision Plus is a CCD imaging system that features the ability to remove
the camera from the Mammotest table, allowing the Mammovision Plus camera to
be installed on the company's HFX diagnostic mammography system. As a result,
near real time digital imaging can be performed in conjunction with standard
diagnostic mammography. This allows the equipment cost to be spread across the
larger number of mammogram procedures that could be performed on a standard
diagnostic mammography system, thus, potentially expanding the company's
market for Mammotest Plus and Mammovision Plus systems. The list price of a
Mammotest Plus system with Mammovision Plus, depending on features selected,
ranges from $195,000 to $225,000.
Mammotest Plus "S"(TM) Surgical System. The Mammotest Plus "S" Surgical
System was introduced in February 1998 in support of the company's surgical
alliance with Ethicon Endo-Surgery, Inc., a
3
<PAGE>
Johnson & Johnson company. The Mammotest Plus "S" is based on the Mammotest
Plus prone biopsy system, with enhancements designed to support the more
advanced techniques performed in the surgical market segment. The list price
of the Mammotest Plus "S" system is approximately $280,000.
HFX(TM) Mammography System. HFX is designed to perform high quality, low
dose diagnostic mammograms quickly, easily and efficiently. Using a
proprietary x-ray tube, the HFX generates excellent spatial resolution,
particularly at the front edge of the image receptor where mammograms
involving magnification are performed. The HFX is available in a two-tube
configuration for integration with the Mammotest, providing a cost-efficient
system capable of performing mammograms as well as stereotactic core needle
breast biopsies. The HFX system ranges in price from $50,000 to $70,000.
HFX Plus(TM) Mammography System. The HFX Plus includes all the features of
the HFX system and adds digital spot imaging. The HFX Plus is designed to
accept the removable CCD camera from a Mammotest Plus stereotactic table. This
allows communication with a Mammovision Plus digital workstation. Dense or
thin, low absorption tissue areas can be evaluated on the digital camera.
Digital technology gives a wider range of contrast controls, allowing enhanced
visualization of faint lesions as compared to conventional film screen
imaging. The list price of the HFX Plus is $62,000.
MammoSound(TM). MammoSound, currently under development, will combine the
Mammotest Plus "S" prone biopsy system and its traditional x-ray imaging
capability with ultrasound imaging. This new concept will add stereotactic
precision to ultrasound biopsy, while adding ultrasound's superior capability,
in some cases, to more accurately characterize breast masses as benign or
malignant. Combining x-ray and ultrasound capabilities utilizing the same
prone table should also be of benefit where floor space is limited.
SenoScan(TM) Digital Mammography System. The company is a leader in the
development of full field of view digital mammography systems. Digital
mammography provides a number of advantages over film screen mammography,
including:
. improved imaging of dense breast tissue through greater ability to vary
image contrast
. reduced radiation dosage to the patient,
. real time imaging, and
. the ability to store images in a digital format, allowing transmission
over high-speed telecommunication networks, thus allowing remote
diagnosis.
The company believes that SenoScan, its full-field digital mammography
system, will offer these advantages. The company believes there is a large
potential market for digital mammography. The SenoScan digital mammography
system may represent a significant technological advance in the imaging of
breast tissue, especially in younger women who generally have denser breast
tissue that is more difficult to successfully image using film screen
mammography technology. As reported by the American Cancer Society, about 20%
of breast cancer cases detected occur in women under age 50.
SenoScan, introduced as a prototype in 1995, is presently installed in six
locations, three of which have performed clinical testing on about 600
patients in support of the company's 510 (k) pre-market clearance application.
Recent information from the FDA indicates a change in the type of study the
FDA is requiring for pre-market clearance of digital mammography and, as a
result, the company is not able to currently project a submission date for a
510 (k) application. No assurance can be given that submission will occur in
1999. See "Business--Government Regulation."
While the company expects that its SenoScan system may cost more than
conventional film screen mammography systems, it believes that the increased
benefits from improved imaging will more than offset the increased capital
costs.
4
<PAGE>
Prototype MR Biopsy System. The company has designed and manufactured a
prototype MR biopsy system that is compatible with the Signa 1.5T magnetic
resonance imaging system provided by GE Medical Systems, which constitutes a
significant portion of the installed base of magnetic resonance imaging
systems. This installed base is believed to consist of about 4,000 operational
systems in the United States. Clinical trials of the prototype system, which
would test the system's ability to reliably biopsy breast lesions using
magnetic resonance imaging as its guidance modality, have not yet begun. The
company believes that the primary use of Breast MR, combined with biopsy
capabilities, will be to provide the physician and patient with additional
information concerning known cancers, and to evaluate the appropriateness of
lumpectomy as opposed to mastectomy.
Electrophysiology Markets
Market Overview
The company estimates that about 350,000 of the 550,000 annual heart attack
deaths in the United States are related to ventricular tachycardia (very rapid
heartbeat) or other cardiac arrhythmias that may cause sudden death. Cardiac
arrhythmias are irregular heartbeats that arise when the normal pattern of
electrical impulses in the heart is disrupted. Cardiac arrhythmias can range
from isolated premature contractions to tachycardia, which may lead to life-
threatening episodes of ventricular fibrillation (rapid, uncoordinated
contraction of the ventricles resulting in a lack of synchronization between
heartbeats and pulse beats).
Atrial fibrillation is a common form of atrial tachycardia. Currently,
approximately 2.2 million people in the United States are believed to have
this condition. Although the condition is not normally in itself life
threatening, the importance of treatment is that, according to an industry
source, atrial fibrillation may cause 75,000 strokes per year. Strokes occur
when clots in the heart are dislodged, resulting in blockage of cerebral
arteries. Episodes of atrial fibrillation can cause this dislodging to occur.
Atrial fibrillation is normally treated by a procedure called cardioversion,
in which an electrical shock is applied to the chest to restore a normal
pattern of electrical impulses in the heart.
The treatment of arrhythmia patients typically involves a diagnostic study
of the electrical functioning of the heart (an "electrophysiology" or "EP"
study). Treatment following the EP study may include: (i) prescription of an
anti-arrhythmic drug, (ii) corrective open heart surgery, (iii) implantation
of a implantable cardiovertor defibrillator ("ICD") or (iv) interventional
therapy such as radio frequency ("RF") ablation. The company estimates that
about 200,000 EP studies are performed each year.
EP studies are performed by inducing an arrhythmia through electrical
stimulation of the heart using a catheter inserted through the skin into veins
leading into the patient's heart. EP studies are increasingly being undertaken
in dedicated EP laboratories. Tilt table testing is also performed to observe
presence or absence of transient fainting when the patient is returned to an
upright position. If it is concluded that the patient should have a surgical
or other interventional procedure, the electrical activity in the patient's
heart is generally mapped in an effort to locate the precise area of the heart
that is causing the arrhythmia or tachycardia. EP x-ray imaging positioners,
tilt-tables, stimulators and recording devices are used during these
procedures, all of which the company manufactures.
The company expects the EP market to continue to remain constant over the
next several years in view of the increased use of ICD implantation, the
development of RF ablation, and the use of new catheter-based technologies for
treating ventricular tachycardia and atrial fibrillation. ICDs are typically
used when patients who have experienced ventricular tachycardia are believed
to be at risk of ventricular fibrillation and sudden cardiac death. The
company expects continued growth in the use of ICDs because of studies
indicating that ICDs may be a more effective therapy for ventricular
fibrillation than current drug therapies. The development of transvenous leads
(involving the use of intravenous catheters) for ICDs and smaller device sizes
that allow chest implantation will allow ICDs to be implanted in an outpatient
setting, probably in a dedicated device implantation suite, as opposed to a
more expensive hospital operating room. The company believes growing use of
chest
5
<PAGE>
implantation of ICDs will provide an expanding market opportunity for the
dedicated device implantation suites, which will require x-ray imaging
equipment.
During the last five years, RF ablation has been increasingly used to treat
atrial arrhythmias such as Wolf-Parkinson-White syndrome. RF ablation involves
locating an electrical abnormality in a chamber of the heart and using
specialized EP catheters to deliver energy from an external source to ablate
(remove) the abnormal tissue. RF ablation has also been used successfully to
treat certain ventricular tachycardia. Current research by
electrophysiologists is studying the use of catheter-based technology in an
interventional procedure to permanently cure patients with recurrent atrial
fibrillation.
Products
The company's strategy has been to develop and market an integrated,
dedicated EP laboratory that contains stimulation, recording and x-ray imaging
capabilities for use in diagnostic and therapeutic EP procedures. An
integrated EP system offers the potential of consolidating controls and
monitors in order to speed EP procedures and reduce personnel requirements.
The company's EP products offer specialized features specifically designed for
the electrophysiologist. The company offers:
. a choice of ceiling or floor mounted c-arm positioners incorporating
motorized isocentric c-arm movement, a feature that allows multiple
fluoroscopic views of the patient's heart without moving the patient
. floor mounted tilt tables
. a ceiling suspended table capable of vertical patient positioning and
. pulse progressive fluoroscopy capable of reducing x-ray dosage by up to
80%.
Until recently, most EP procedures were performed in cardiac catheterization
laboratories or performed with mobile fluoroscopic systems. The company, with
the cooperation of the University of Colorado Health Sciences Center,
developed the first dedicated EP system in 1985, and since that time has sold
over 100 dedicated EP systems, primarily to teaching hospitals in the United
States.
EP/X(TM). The EP/X system, introduced in 1995, is an economical, state of
the art single plane x-ray imaging system designed to meet the general EP
requirements of most community and teaching hospitals. The EP/X is offered
with the company's patented automatic pulse progressive fluoroscopy system as
an option. The list price of the system ranges from $400,000 to $450,000. As a
result of healthcare industry cost containment pressures, many of the
company's EP system orders include the EP/X system.
EP/X/2/(TM). The EP/X/2/, a cost-effective, ceiling suspended, bi-plane
fluoroscopy system, is designed to meet all the positioning requirements of
electrophysiologists, with easy access to the patient. The company believes
that bi-plane imaging will be important for new, developing EP procedures such
as catheter treatment for ventricular tachycardia or atrial fibrillation. The
company believes a ceiling suspended system is versatile enough for use in
either a dedicated EP laboratory or in a surgical suite. As a lower cost
alternative, the EP/X/2/ complements the company's bi-plane Cardiac CX/Pegasus
imaging system. The list price of the EP/X/2/ system is well below the lowest
price of currently available competing systems. FDA 510(k) clearance for the
EP/X/2/ was obtained in 1997. The EP/X/2/ system, which has a list price of
$800,000, is installed in several leading EP laboratories throughout the
United States.
Cardiac CX/Pegasus(TM). The Cardiac CX/Pegasus is a fully-integrated bi-
plane system for cardiac special procedures laboratories. The Cardiac
CX/Pegasus has a list price of over $1,000,000.
EPIC(R) EPIC is a computerized image management system used to integrate and
display x-ray images and electrocardiogram ("ECG") signals during an EP
procedure. The EPIC can handle both bi-plane and single plane images and
provides the ability to display three ECG signals from the EPACE recording
system on the x-ray imaging system in both the control room and the procedure
room.
6
<PAGE>
EP Stimulators The company currently markets the DTU-215 EP Stimulator, a
four-channel stimulator for use in EP laboratories and has under development
the EP/Stim, a computer-driven stimulation system, that would allow the
physician to load his personal protocols for performing electrophysiology
procedures. The DTU-215 EP Stimulator lists for $22,000. During 1998, the
company continued work on a 510(k) notification for the EP/Stim to the FDA,
and now believes this submission will occur during 1999.
Competitors in the EP market such as GE Medical Systems, Philips
Electronics, Siemens A.G., and Toshiba America Medical Systems, Inc. provide
single-plane systems for EP laboratories at prices ranging from $500,000 to
$600,000. The company's EP/X single-plane EP system, designed specifically for
the requirements of the electrophysiologist, is offered at a price below the
competition.
Endovascular and Interventional Markets
Market Overview
The most common form of cardiovascular disease is atherosclerosis, a disease
characterized by the thickening of the arteries caused by deposits of a fatty
substance called "plaque". Atherosclerosis affects both coronary and
peripheral arteries. Repair of partially blocked arteries that are impairing
the normal flow of blood has traditionally been through open surgical
procedures performed by vascular surgeons in a hospital operating room. In a
similar setting, vascular surgeons repair aneurysms (balloon like enlargements
of an artery) which, if left untreated, can rupture and cause death.
As an alternative to open surgery, catheter techniques have been used for
over a decade to treat a significant number of vascular disorders. These
techniques are performed through the skin, rather than using open surgery, and
thus are less-invasive and costly. High performance x-ray imaging guidance is
required. The procedures were initially developed by cardiologists and
radiologists and performed in cardiac catheterization or angiographic
laboratories in hospital cardiology or radiology departments.
Angioplasty, one of the most frequently performed procedures, involves x-ray
imaging guidance of a catheter introduced into a blood vessel. The catheter is
guided to the vascular narrowing and a balloon is inflated to reopen the
artery to normal flow. While peripheral angioplasty has been quite successful,
a significant portion of treated vessels close up again over time. More
recently, stents, delivered to the narrowing of the artery on a catheter, have
been implanted. Studies have shown that stents keep the artery open longer.
Catheter-based techniques to remove plaque have also been successful and are
frequently performed in conjunction with stent implantation.
Vascular surgeons are increasingly involved in hospital purchasing decisions
for x-ray imaging systems and are becoming trained in the performance of these
newer, less-invasive vascular (non-coronary) procedures. Historically,
relatively less sophisticated mobile c-arm intensifiers have provided the
required x-ray imaging capability for vascular surgeons. Now, however, more
complex vascular procedures, including carotid stenting and abdominal aortic
aneurysm repairs using stent grafts, require more complex x-ray imaging
capability.
Abdominal aortic aneurysms are vascular enlargements which are difficult to
treat and, if left untreated, become increasingly susceptible to rupture,
usually resulting in death. Several companies have developed stent grafts that
are deployed across the aneurysm following the introduction of a catheter
through the skin. The x-ray imaging requirements for this form of repair are
demanding and typically cannot be met by the capabilities of mobile c-arm
intensifier systems. The company believes that stent grafts will eventually
provide a less-invasive method of treating the estimated 190,000 abdominal
aortic aneurysms diagnosed yearly in the United States. Currently, only an
estimated 45,000 patients undergo open surgery annually, in large part due to
the high mortality associated with the procedure.
In addition, the use of laparoscopic cholecystectomy (minimally-invasive
gall bladder removal) procedures has grown substantially over the last several
years. These procedures usually require the use of x-ray systems to perform
intraoperative cholangiograms (x-ray studies of the gallbladder). The company
believes that continued
7
<PAGE>
growth in the use of laparoscopic and other minimally-invasive procedures will
increase the demand for dedicated x-ray systems in the operating room.
The company believes that vascular surgeons will continue to prefer
catheter-directed techniques such as peripheral angioplasty and stent
placements in an operating room setting using angiographic x-ray imaging
systems with similar capabilities as found in dedicated x-ray laboratories.
The company also believes that vascular surgeons will prefer newly evolving,
high risk procedures such as repairs of abdominal aortic aneurysms and carotid
and iliac stenting in an operating room where open surgery will be immediately
available if necessary.
Products
2000/2001 Series. The 2000/2001 Series of products include specialized x-ray
imaging systems designed to meet the x-ray imaging needs of the operating room
during open heart and other open surgical procedures. Specific features
include:
.a ceiling suspended isocentric c-arm x-ray imaging system,
.state of the art angiographic and digital image management capabilities,
.a surgical table with motorized control for rotation, tilting and
elevation
. an unobstructed 80 inch cantilevered carbon fiber table top that supports
the patient and permits full body x-ray imaging, and
.with the 2001 system, increased x-ray tube heat capacity and the ability
to add a 12 inch image intensifier.
An important feature of the 2000/2001 Series systems is high line variable
frame rate progressive fluoroscopy, which allows x-ray dosage reduction of up
to 80% with no loss in image quality. The company believes this feature is
important because many technicians who perform catheter placements, pacemaker
implantation and general orthopedics are not trained in radiology.
The company is not aware of any other company making dedicated x-ray imaging
systems for surgery with features similar to those of the 2000/2001 Series. A
number of manufacturers provide low cost mobile c-arm intensifier systems
designed for the x-ray imaging requirements during surgery. However, the
2000/2001 Series is believed to have several advantages over a mobile c-arm,
including improved image quality, ease and speed of positioning, x-ray dose
reduction and on-line angiographic image processing. The company believes
these product features are particularly important to endovascular surgeons.
Since 1991, the company's 2000/2001 Series systems have been distributed by
International Surgical Systems under a marketing agreement. ISS's list price
for the 2000/2001 Series products is approximately $499,000.
Imager III. The company's Imager III system is a universal x-ray imaging
system designed for a wide variety of endovasular and other interventional
radiology procedures. Incorporated in these systems are digital image
processing computers, which allow reduced x-ray dosage and improved image
quality, and sophisticated positioning control over the patient and the x-ray
source, permitting the physician to efficiently achieve all the angles
necessary to complete a procedure.
With its own product (the DPS-100) and though arrangements with the digital
processing companies Infimed and Camtronics, the company offers as an add-on
to the Imager III and other general purpose systems, the capability to
digitally capture and enhance images, allowing immediate diagnosis. The image
archiving capabilities and the possibility of fewer images per case offered by
digital capture devices can reduce film and personnel costs.
The list price of Imager III systems ranges from $500,000 to $800,000
depending on the components included.
8
<PAGE>
GENERAL RADIOLOGY PRODUCTS
The company also sells other diagnostic x-ray imaging systems and other
products used for general x-ray procedures. These systems are sold
domestically and internationally through direct and dealer distribution
channels for use in hospitals, clinics, and physician's offices for general
radiographic and fluoroscopic screening.
TRAUMEX(R). The company's Traumex x-ray imaging system provides unique
positioning capabilities requiring minimal patient movement, making it well
suited for emergency room applications. It is also a versatile general
radiographic system, allowing x-ray of the chest, skeleton, head, or other
extremities. The list price of the Traumex ranges from $140,000 to $200,000.
RAD DX/MX. The company manufactures and sells Rad DX, Rad MX, and other
general radiographic systems to hospitals and clinics. The Rad DX product line
includes x-ray imaging products used in clinics and physicians' offices, and
has a list price of about $35,000. The Rad MX, generally sold to hospitals,
has a list price of $80,000 to $120,000.
DR1000C DIGITAL CHEST SYSTEM. Under a product development and marketing
agreement with Direct Radiography Corp., a subsidiary of Sterling Diagnostic
Imaging, Inc., the company has developed a dedicated digital chest system
incorporating Sterling's DirectRay(TM) direct-to-digital x-ray capture system.
To date, the DR1000C is installed and operational at six sites, with
encouraging results and market reception. See "Strategic Alliances". The list
price of the DR1000C is approximately $350,000.
DR1000 DIGITAL TRAUMEX. The DR1000 Digital Traumex is a digital version of
the company's versatile and highly successful Traumex emergency room and
general purpose x-ray system. Incorporating Sterling's DirectRay(TM) direct-
to-digital xi-ray capture system, a DR1000 prototype is expected to be
completed later this year. The DR1000 is expected to have a list price of
$395,000.
OEM AGREEMENTS
The company also designs and manufactures specialty x-ray imaging components
and subsystems for several leading medical products companies as an OEM. Sales
under OEM contracts amounted to about 24% of the company's 1998 total
revenues. OEM relationships can provide access to new technologies, while
sharing their development cost. Manufacturing cost savings can also be
achieved, when the components and subsystems can be used in higher volumes. In
most cases, the company retains an ownership interest in product designs.
These OEM contracts expire on various dates in 1999 and 2000. Under some
circumstances, contracts provide that orders may be reduced or terminated
earlier than the contract's expiration date. Sales under OEM agreements can
fluctuate significantly.
GE Medical Systems. GE Medical Systems, currently the holder of a 16%
interest in the company, has been a significant customer, accounting for
approximately 5.9% of the company's 1998 total revenues. GE Medical Systems
has purchased Tilt-C positioners from the company under the terms of its OEM
contract. The Tilt-C positioner is a multi-purpose 90 degree tilting table
with a cantilevered table top and sophisticated positioner controls. These are
used in biopsies and other interventional procedures, as well as in general
imaging studies. On March 29, 1999, the company announced an agreement with
General Electric Company, on behalf of GE Medical Systems, under which 826,666
or 62% of the 1,333,333 shares of Series D Convertible Preferred Stock
currently owned by GE Medical Systems will be exchanged for a non-exclusive
right to manufacture the Tilt-C system. Completion of the necessary technology
transfer is required by mid-April, 1999. The company expects to continue its
manufacturing activity for GE Medical Systems through at least December 1999,
the original expiration of the OEM Contract. See also the related discussion
at "Item 5-Market for Registrant's Common Equity and Related Stockholder
Matters--Risks Associated with Shares Eligible for Future Sale" later in this
report.
Varian. Under its OEM contract with Varian, which expired in October 1998,
the company provided a line of x-ray generators and imaging systems as
components of Varian's Ximatron radiotherapy simulator system. Under
requirements of this contract, the company expects to continue to supply
Varian with parts for such system components for several years.
9
<PAGE>
Storz. Under its ten-year OEM agreement with Storz, which expired in 1998,
the company designed and manufactured the c-arm x-ray imaging system used with
Storz Medical's Modulith SLX lithotripter (a non-invasive system for breaking
kidney stones), which is sold worldwide. Although it is unknown whether the
company will supply Storz with additional systems in the future, the company
expects to continue furnishing parts for the system components previously sold
to Storz, as required by the OEM contract.
Picker. In March 1997, the company agreed to supply cardiac catheterization
systems for international markets. The company is currently discussing with
Picker whether to continue this relationship. Under a previous OEM agreement
that expired in February 1997, the company supplied Picker with radiographic
and fluoroscopic systems, including the x-ray generator, imaging chain, table
and tube stand. The company expects to continue to provide parts for such
systems over the next several years.
Dornier. The company has a contract, which runs through December 2001, to
supply Dornier with x-ray imaging systems for sale with Dornier's lithotripter
systems. Dornier systems are sold worldwide, and have been sold in the United
States since 1995 when FDA clearance was received. By mutual agreement, the
company is not currently supplying systems under this agreement.
ISS. The company sells its 2000 and 2001 Series specialized x-ray imaging
system to ISS under an OEM agreement. Under this agreement, ISS is responsible
for sales and marketing of these systems, while the company is responsible for
installation, applications training and service. ISS currently has five direct
sales people selling the 2000/2001 Series in the United States. Both companies
are permitted to market the product outside of North America. This agreement,
which originally expired in December 1998, has been extended to December 2000.
Risks Associated With OEM Agreements--Changes in OEM customer business
strategies, fluctuations in product demand, or contract renegotiations with OEM
customers could adversely affect shipments and/or profitability under OEM
contracts.
Many of the company's OEM customers are also competitors and have
significantly larger installed customer bases, financial, management,
manufacturing, sales, marketing, and other resources than the company. The
business strategies and manufacturing practices of the company's OEM customers
are subject to change and such changes may result in decisions to seek other
sources for the products currently manufactured by the company or to
manufacture these products internally. Additionally, these OEM customers
typically seek to obtain price concessions or the pass through of any cost
savings achieved by the company in the form of lower prices. The company's OEM
contracts are usually non-exclusive. OEM customers generally may modify, limit
or terminate the contract or purchase orders under the contract on short notice
with modest or no penalties. OEM customer order levels are influenced by
factors such as the OEM customer's product sales, changes in product or
marketing strategy, changes in components of the end product manufactured by
others and development of new products. Additionally, the timing of product
orders under OEM contracts has fluctuated and is likely to continue to
fluctuate on a quarterly or annual basis. Under OEM contracts, the company is
typically required to design, develop and manufacture its products to the OEM
customer's specifications and, from time to time, may be required to correct
product deficiencies. OEM agreements involve complex products, and changing
product specifications and requirements may, from time to time, lead to the re-
negotiation of these agreements. These renegotiations may result in
disagreements that could adversely affect relationships with OEM customers. For
example, in late 1997 and early 1998, the company was involved in litigation
under an OEM contract. Subject to appeal, an unfavorable outcome regarding
pricing was obtained in this instance. There can be no assurance that this or
other OEM relationships and revenues will not be adversely affected in the
future by such disagreements. Moreover, order rates under the company's OEM
contracts can decline over the term of the agreement and may not be renewed
upon expiration, causing revenues to decline significantly. The company may not
be able to replace revenues lost in such situations. There can be no assurance
that the company will be able to maintain its existing OEM relationships, or to
replace the loss of any of its OEM relationships with other business. Failure
to do so could have a material adverse effect on the company's business and
profitability.
10
<PAGE>
Sales and Marketing
In the United States, the company currently markets its products through its
direct sales force and certain dealers. Direct sales offer the company higher
margins, more control over the sales process and customer contacts, and ongoing
service revenues. The company believes that sales of its more sophisticated
products such as breast cancer, EP and endovascular systems may be enhanced by
a focused and dedicated sales force. As a result, the majority of the company's
sales of Mammotest and EP systems are made through its direct sales force. The
company believes that general radiology systems can be more effectively sold by
dealers because such products require broader distribution and more competitive
pricing. Therefore, the company primarily markets its general radiology systems
through dealer organizations. Some of these dealers market the company's entire
product line, while others focus exclusively on the general radiology market.
As of December 31, 1998, the company had 23 direct sales people whose
territories primarily cover large metropolitan areas and about 20 independent
dealers covering the remainder of the United States. The company also expects
to continue to benefit from a marketing alliance with Ethicon Endo-Surgery,
which has a direct sales organization and marketing resources substantially
larger than those of the company. See "Strategic Alliances."
Historically, the company's marketing efforts have been focused in the United
States. However, the company has also attempted to expand its international
marketing efforts to support the company's expansion into the European, Asian
and Latin American markets. The company formed subsidiaries in Australia
(1984), Europe (1993), and China (1996) to manage its sales and its dealer
relationships in Asia and Europe. International sales have also been made
through dealers in Latin America and the Middle East. In recent years, the
company's efforts to expand internationally have met with limited success.
Therefore, the marketing alliances that have produced encouraging results in
the United States may, in the future, receive greater emphasis internationally
as a means of expanding the company's markets. As of December 31, 1998, the
company had 10 direct sales people and about 45 dealers conducting the
company's international sales efforts.
The company's marketing activities include trade shows, advertising in
professional journals, telemarketing and the administration of seminars,
conferences and physician training programs. The marketing group develops sales
leads and assesses customer satisfaction with the company's products, as well
as with direct and dealer service performance.
The company's service organization is responsible for installing its products
and providing warranty service. Products sold by the direct sales force carry
limited warranties covering parts and labor for periods ranging from six to
twelve months. Products sold through dealers and to OEM customers carry more
limited warranties, with terms ranging from six to twelve months and typically
covering only parts or components. Service personnel offer maintenance service
either under contracts or at hourly rates. The direct service organization also
provides maintenance service in some foreign countries. In other foreign
countries, the company utilizes dealers and third parties to provide
maintenance service for its products. As of December 31, 1998, the company
employed 42 field and technical support engineers and 16 administrative and
management personnel in its U.S. service organization.
International Operations--The costs, uncertainty of product acceptance, and
other elements of doing business internationally could affect whether the
company can be successful in establishing profitable international operations.
Revenues from customers based outside the United States accounted for 15.6%,
18.7%, and 21.2% of the company's total revenues in 1998, 1997, and 1996,
respectively. These revenues included sales to foreign OEM customers of 11.5%,
6.8%, and 11.7% of the company's 1998, 1997, and 1996 total revenues,
respectively. In addition, the company has OEM contracts with several foreign
and multinational companies that distribute the company's products
internationally and within the United States. Risks of doing business outside
the U.S. include:
.the expense and difficulty of establishing, expanding, and managing
international operations,
11
<PAGE>
. the uncertainty of market acceptance of the company's products,
. the difficulty of enforcing agreements, collecting receivables, and
protecting intellectual property in foreign countries,
. the potential imposition by foreign countries of additional withholding
taxes, income taxes, tariffs, or other restrictions on foreign trade, and
. potential difficulties in obtaining U. S. export licenses.
In 1998 and 1997, the company experienced reductions in its international
business. There can be no assurance that this market will improve or that any
of the foregoing risks will not result in a material adverse effect on the
company. See Note 10 "Operating and Geographic Segment Information", of Notes
to Consolidated Financial Statements for additional information.
Strategic Alliances--The company's ability to meet manufacturing demand,
achieve market acceptance of new products, and obtain financial sponsorship
will determine the success of strategic alliances.
The company has strategic marketing and distribution alliances that it
believes will allow it to compete more effectively in the markets for its
products.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company. Since October 1997,
the company has been operating under a marketing partnership with Ethicon
Endo-Surgery, Inc. for the marketing and sale of Mammotest Plus "S", a version
of the company's Mammotest Plus prone biopsy system designed for the
requirements of the surgical market. This system has a list price of $280,000.
To date, the company has been able to attain sufficient manufacturing capacity
necessary to meet the additional demand generated by this marketing
partnership. However, under the terms of this relationship, in the event the
company in the future were unable to meet certain potential delivery
obligations, Ethicon Endo-Surgery could have the right to a minimum five year
non-exclusive license to manufacture and sell certain company products. Any
such license would give the company specified royalty rights on each sale.
In December 1998, the company entered into an agreement with Ethicon Endo-
Surgery Europe for the distribution of the Mammotest system in Europe. Under
this agreement, the company will provide applications and service support,
while EES Europe is responsible for sales of the Mammotest system.
Sterling Diagnostic Imaging, Inc. In November 1997, the company entered into
an alliance with Digital Radiography Corp., a subsidiary of Sterling
Diagnostic Imaging, Inc. under which the company and Sterling are jointly
developing digital radiographic systems utilizing Sterling's FDA-cleared
DirectRay(TM) digital image detector technology with the company's positioning
and x-ray components. Potential clinical benefits of digital image acquisition
over film-based imaging include:
. fewer retakes,
. faster diagnosis,
. remote image interpretation,
. image integration with other patient records,
. reduced film and other supply costs, and
. higher equipment utilization.
Under an agreement in principle, manufacturing, installation, service, and
support functions would generally be performed by the company, while marketing
and sales would be performed by both companies. The company is in the process
of finalizing aspects of its agreement with Sterling.
The first system developed under this alliance was a dedicated digital chest
system (DR1000C), which is now installed in six sites. The next major product
currently being developed is a digital version of the company's versatile and
highly successful Traumex emergency room and general purpose x-ray system
(DR1000). A prototype is expected to be completed later in 1999. See "General
Radiography Products".
12
<PAGE>
In January 1999, the Agfa-Gevaert Group announced an agreement to acquire the
parent company of Direct Radiography Corp., but not Direct Radiography Corp.
itself. In order to continue product and market development, Direct Radiography
must obtain alternative financial sponsorship. There can be no assurance that
such sponsorship can be obtained. In the event Direct Radiography were to cease
operations, the company could suffer inventory and other losses.
Backlog
The company's backlog generally includes only product orders for which
delivery is requested within the upcoming twelve months. Although the company
has some multi-year OEM agreements and sometimes has OEM or other orders with
longer than twelve month lead times, such orders are included in backlog only
when the requested delivery date falls within a twelve month period.
As of December 31, 1998 and 1997, the company's backlog was approximately
$26.9 million and $24.2 million, respectively. Backlog as of any particular
date should not be relied upon as being indicative of the company's revenues
for any future period.
Research and Development
The company has a number of potential new products in various stages of
development. Currently, the company's research and development efforts are
focused on the development of SenoScan, its full field digital mammography
system employing CCD imaging technology. In addition, the company is expending
significant research efforts to integrate breast ultrasound with the Mammotest
system (MammoSound) and other advanced image processing applications. Research
and development expenditures totaled $6.4 million, $6.0 million and $6.7
million in 1998, 1997, and 1996, respectively.
The National Cancer Institute, through payments made to certain members of
the National Digital Mammography Development Group (a consortium of GE Medical
Systems and four universities), has provided limited funding for the clinical
testing of SenoScan.
The company also has a research arrangement with the University of Toronto's
Department of Medical Physics to jointly evaluate the company's digital
mammography detector system.
The company believes that its ability to develop technical innovations and
apply them to new products designed for targeted clinical applications has been
and continues to be important to its success. The company's key areas of
engineering expertise include digital image processing, structural mechanical
design, microprocessor control of servo systems, high voltage x-ray generator
design and high resolution video systems. As of December 31, 1998, the company
employed 61 engineers and technicians in research and development.
Risks of Technological Change and New Products--Quick response to technological
change will be critical to the company's future success.
The market for the company's products is characterized by rapid and
significant changes in competitive technologies, evolving medical industry
standards, and the frequent introduction of new products. Alternative surgical
procedures or technologies or new medications may also be developed and
marketed. Products based on new technologies could replace or reduce the
importance of current procedures that utilize the company's products and render
these products noncompetitive. Therefore, the company's success will depend in
part on its ability to respond quickly to new product introductions, marketing
campaigns and medical and technological changes through the development of new
products. There can be no assurance that the company will be able to develop
new products in the future in a timely or cost-effective manner, if at all, or
that the company's current products will not be rendered obsolete or
noncompetitive.
13
<PAGE>
Risks of New Product Development and Market Acceptance--The success of new
products is dependent on successful product design efforts, receipt of FDA
clearances, and upon market acceptance.
The company has a number of potential new products in various stages of
development. Current research and development efforts are focused on the
development of SenoScan, its full-field digital mammography system, for which
clinical trials are continuing but which has not yet received pre-market
clearance from the FDA. In addition, significant efforts are being expended on
ultrasound, full-field digital mammography, and associated advanced image
processing applications. These products involve technological innovation and
require significant planning, design, development and testing at the
technological, product and manufacturing process levels. Significant
investments in research and development, equipment, inventory, manufacturing
and marketing are also required. Lengthy and expensive clinical trials could
also be required prior to submission to the FDA for FDA clearance or approval.
There can be no assurance that the company will be able to successfully design,
manufacture and market these new products or that the new products will receive
FDA clearance or approval. In addition, the company's newest products may be
used with minimally-invasive surgical procedures and the company believes that
it must demonstrate to physicians and managed healthcare organizations the
clinical benefits, safety, efficacy and cost-effectiveness of its products for
such procedures. In particular, the company must demonstrate that its products
are an attractive alternative to other products and methods that may be widely
accepted. There can be no assurance that surgeons will embrace such techniques
as replacements for open surgical procedures or that hospitals will be willing
to invest in and utilize the company's products. Lack of widespread acceptance
of these products could have a material adverse effect on the company's future
revenues and earnings. See "--Research and Development."
Competition--The strategies of competitors, some of which hold greater
resources than the company, could adversely impact the company's success.
The company encounters and expects to continue to encounter intense
competition in the sale of its products. The company believes that it
maintains, with respect to each of its products, distinct competitive
advantages in one or more of these areas:
. the clinical aspects of the products,
. product features,
. speed of introduction of new products utilizing changes in technologies,
performance and quality,
. upgrade flexibility,
. price, and
. customer service
The company's competitors include large multinational corporations, including
GE Medical Systems, Siemens, Philips, Toshiba, Shimadzu, and Picker, as well as
a number of other companies such as Trex Medical Corporation. These companies
typically have a larger installed base and far greater financial, management,
manufacturing, sales and marketing, and other resources than the company. As a
result, they may be able to more quickly adapt to new or emerging technologies
and changes in customer requirements, or to devote greater resources to the
development, manufacture, promotion and sale of their products. Moreover, a
significant portion of the company's sales are to medical equipment companies
who integrate the company's products into their own systems or resell these
products under their own label. There can be no assurance that such companies
will not choose to purchase from alternative sources or internally manufacture
competing products. The company also faces competition from sellers of used x-
ray imaging equipment, particularly general radiology systems, at prices
substantially below the prices of the company's new products. In addition, the
company competes for acquisition opportunities, OEM and service contracts and
experienced personnel.
The company's Mammotest system principally competes with the prone-
positioning breast biopsy system manufactured by Lorad, a division of Trex
Medical, which Lorad has aggressively priced and marketed. Many
14
<PAGE>
larger companies, including GE Medical Systems, Philips and Siemens, also offer
stereotactic add-on systems. In December 1998, following the acquisition of
U.S. Surgical Corporation by Tyco Corporation, Trex announced the termination
of its OEM agreement with U. S. Surgical for the sale of the stereotactic table
manufactured by Lorad on a private label basis. U.S. Surgical had been
competing aggressively and successfully within the surgical stereotactic core
needle biopsy market and, although long-term competitive conditions may improve
for the company as a result of the decision to terminate the OEM agreement with
Lorad, the near-term competitive implications are uncertain. No assurance can
be given that the decision will not have an unfavorable impact on the company's
sales of its Mammotest systems in the near term. See Item 3 "Legal Proceedings"
for a discussion of the company's patent infringement litigation against Lorad.
Government Regulation--The company's success is dependent on complying with the
complex regulatory requirements of a variety of U.S. and international
governmental agencies.
The company's business is subject to substantial regulation by the FDA and
equivalent agencies in foreign countries. Failure to comply with applicable
regulatory requirements can result in, among other things, civil and criminal
fines, orders to repair or replace devices or to refund the device purchase
price, suspensions and withdrawals of approvals, product recalls, detentions or
seizures, injunctions and criminal prosecutions.
FDA regulations require manufacturers of medical devices to adhere to "Good
Manufacturing Practices", which include testing, quality control and
documentation procedures. The company's manufacturing facilities are subject to
periodic inspection by the FDA. In March 1995, the company was issued a Warning
Letter by the FDA concerning documentation and other deficiencies at its Denver
facility. The company rectified these deficiencies and resolved this matter
with the FDA later that year. Following an inspection which concluded in
December 1996, the FDA issued Inspectional Observations Form 483 ("Form 483")
and a Warning Letter concerning manufacturing practices at its Denver facility.
The FDA requested a written response to the Warning Letter regarding planned
corrective actions and a favorable third-party certification of the company's
manufacturing and quality systems. These actions were completed. In October
1998, following a periodic inspection, the FDA issued a Form 483 regarding
possible deficiencies in manufacturing, quality, and documentation practices.
The company has submitted its response to the Form 483 and is instituting
corrective actions.
Failure to satisfy FDA requirements can result in the company's inability to
receive awards of federal government contracts, to receive new marketing or
export clearances for products manufactured at its Denver facility, or FDA
enforcement actions including, among other things, product seizure, injunction,
and/or criminal or civil proceedings being initiated by the FDA without further
notice. The recent issuance of another Form 483 increases the possibility that
one or more of these sanctions could be imposed in the future. Although the
company strives to operate within the requirements imposed by the FDA, there
can be no assurances that these deficiencies can be corrected or that the
company will be able to satisfy FDA compliance concerns in the future. Ongoing
FDA compliance reviews and/or related delays in future product clearances could
have a material adverse effect on the company.
The FDA has post-marketing controls that include a requirement to file
medical device reports when the company becomes aware of information suggesting
that one of its marketed products may have caused or contributed to a death,
serious injury or serious illness or has malfunctioned in a way which could
lead to that result. The company must utilize field performance information,
which includes any reportable events, in its quality control system to make any
changes necessary to reduce or eliminate similar events in the future. The FDA
utilizes Medical Device Reports to determine whether it should exercise its
enforcement powers, such as mandatory product recalls, temporary suspensions of
approvals, or withdrawal of 510(k) marketing clearances or premarket approvals.
The filing of Medical Device Reports indicating unexpected product hazards or
the failure to comply with medical device reporting requirements could have a
material adverse effect on the company.
Each of the company's products is required to receive FDA clearance or
approval prior to commercialization. To date, all of the company's products
have been classified by the FDA as Class II medical devices and have been
eligible for FDA marketing clearance under the FDA's 510(k) premarket
notification
15
<PAGE>
process, which is generally less time consuming than the more involved pre-
market approval process for Class III medical devices (a "PMA"). The company
believes that most of its currently anticipated future products and substantial
modifications to existing products will be eligible for the 510(k) pre-market
notification process. However, the FDA has not yet classified full-field
digital imaging mammography systems like the SenoScan system being developed by
the company. A 1996 FDA memorandum suggested that clearance for full-field
digital imaging mammography systems might be obtained through a 510(k)
notification with clinical trials involving approximately 500 subjects. More
recent FDA communications are less clear as to what clinical standards must be
met and, in late 1998, the 510(k) digital mammography submission by Trex
Medical was rejected by the FDA. The company has acquired the previously
suggested minimum number of patients for its clinical trials, but is now
gathering additional clinical data, in response to the FDA's revised guidance.
Efforts toward a 510(k) submission for SenoScan are on-going. This submission
is significantly later than originally anticipated due to start-up equipment
issues, patient acquisition delays, and conflicting guidance from the FDA
regarding the submission.
If the FDA were to indicate that a PMA is required for any of the company's
new products, that application would require extensive clinical studies,
manufacturing information and most likely a review by a panel of experts
outside the FDA. Clinical studies would need to be conducted in accordance with
FDA requirements. Failure to comply with FDA requirements could result in the
FDA's refusal to accept the data or the imposition of regulatory sanctions. FDA
review of a PMA application can take significantly longer than that for a
510(k) pre-market notification and could take several years to complete. There
can be no assurance that the necessary applications clearances or approvals for
any of the company's new products, including SenoScan, will be made or obtained
on a timely basis, if at all. Failure to obtain necessary regulatory approvals,
the restriction, suspension or revocation of existing approvals, or any failure
to comply with regulatory requirements could have a material adverse effect on
the company's business, financial condition and results of operations.
Sales of medical devices outside of the United States are subject to FDA
export and international regulatory requirements that vary from country to
country. The time required to obtain approval for sale internationally may be
longer or shorter than that required for FDA clearance or approval, and the
requirements may differ. There can be no assurance that the company will obtain
regulatory approvals in such countries or that it will not incur significant
costs in obtaining or maintaining its foreign regulatory approvals. The company
has obtained the certifications necessary to permit the "CE" mark to be
attached to those products currently being sold in Europe. The CE mark is an
international symbol of quality that is now required for sales into the
countries which are members of the European Union. While the company has
approval to sell into the European Union, there can be no assurance that the
company will be able to obtain other international regulatory approvals. In
addition, significant costs and delays may be encountered in obtaining such
approvals.
The company is also regulated by the FDA under the Radiation Control for
Health and Safety Act of 1968 which specifically addresses radiation emitting
products. Under this law, the company must submit initial reports on any new x-
ray systems that require certification. In addition, the company must submit
installation reports to the FDA certifying compliance with installation
instructions of the manufacturer. Under certain circumstances, the company also
is required to submit Product Defect Reports concerning its radiation emitting
products to the FDA and, sometimes, to the first purchasers of the products.
Product Defect Reports describe any safety related product defects or the
failure of a product to conform to an applicable standard of which the company
has become aware. Additionally, the company is required to submit Accidental
Radiation Occurrence reports to the FDA whenever one of its products
accidentally releases radiation that results in an injurious or potentially
injurious exposure to any person. However, the company need not file both a
Medical Device Report and an Accidental Radiation Occurrence report on the same
incident. A failure to comply with these regulations could have a material
adverse effect on the company. Furthermore, discovery of unexpected product
hazards or failures to meet required standards through the reporting system
could also have a material adverse effect on the company.
The company is also subject to other Federal, state, local and international
laws and regulations related to worker health and safety, environmental
protection and export controls. The company believes it is in compliance in all
material respects with these other laws and regulations and that maintaining
such compliance will not have a material financial impact on the company's
capital expenditures, earnings or competitive position.
16
<PAGE>
Government Reimbursement--The company's future success is very dependent on the
reimbursement policies of various governmental agencies.
Medicare reimbursement for hospitals represents about 40% of all hospital
revenues. Since 1983, Medicare has limited reimbursement to a fixed amount,
based on specified categories of diagnosis known as Diagnosis Related Groups.
Hospital profit margins have been reduced significantly since the introduction
of fixed reimbursement amounts based on Diagnosis Related Groups. Therefore,
hospitals have incentive to use less costly treatment methods. If a new
technology is considered to be more cost effective, hospitals will frequently
make capital expenditures to provide cost savings. Frequently, Medicare
reimbursement rates are reduced to reflect the adoption of a new procedure or
technique and, as a result, hospitals are generally willing to implement new
cost saving technologies before these downward adjustments in rates become
effective. The company believes that since minimally invasive surgical
techniques are generally less expensive than open or conventional surgery, its
stereotactic breast biopsy, electrophysiology and endovascular systems provide
hospitals the opportunity to reduce costs and, therefore, in the context of a
fixed reimbursement structure, the company may benefit from cost containment
programs.
In 1991, the Health Care Financing Administration published rules to change
the method of capital reimbursement for hospitals. The rules changed capital
reimbursement from a system based on costs to one based on prospective payment.
The rules provide for a ten year transition and permit hospitals with unusually
low or high capital reimbursement methods to be reimbursed fairly. The company
believes that these capital reimbursement rules impact facilities expansion
more heavily than medical equipment purchases.
Beginning in 1992, Medicare phased in over a five year period a system under
which reimbursements to physicians are based on the lower of their actual
charges or a fee schedule amount based on a "resource-based relative value
scale." This replaced a "charge-based" fee schedule, and generally lowers the
reimbursements received by radiologists and cardiologists from the previous
method.
The Federal government also regulates the reimbursement of fees related to
certain diagnostic procedures or medical conditions and capital equipment
acquisition costs connected with services to Medicare beneficiaries. Other
legislation has limited Medicare reimbursement of these fees, which has the
effect of limiting the availability of reimbursement for procedures or
conditions and, as a result, may inhibit or reduce demand by healthcare
providers for the company's products. For example, the Balanced Budget Act of
1997, enacted by Congress in August 1997, reduces capital expenditure payments
to hospitals by some two percent for the period October 1, 1997 through
September 30, 2002. Additionally, hospitals may continue to face other capital
constraints which prevent them from investing in such equipment. In addition,
widespread use of procedures utilizing the company's SenoScan digital or breast
magnetic resonance imaging mammography systems, which are currently under
development, would likely require reimbursement in excess of those currently
permitted under Medicare guidelines. As a result, the demand for these systems
may be limited.
While the company cannot predict what effect the polices of government
agencies and other third party payers will have on future sales of the
company's products, there can be no assurance that such policies would not have
a material adverse impact on the business of the company.
Manufacturing
The company's products are manufactured at its manufacturing facility in
Denver, Colorado. Production processes include machining, fabrication, printed
circuit board assembly and testing, subassembly, system assembly and final
testing. The company has invested in various automated and semi-automated
equipment for the fabrication and machining of parts and assemblies
incorporated in its products. The company may from time to time further invest
in such equipment when cost-justified. The company's quality assurance program
includes various quality control measures from inspection of raw materials,
purchased parts and assemblies through on-line inspection.
The company's manufacturing processes are, for the most part, vertically
integrated, although some outsourcing is employed to take advantage of
economies of scale at outside manufacturing facilities and to
17
<PAGE>
alleviate manufacturing bottlenecks. The company purchases materials and
components from various suppliers that are either standard products or built to
company specifications. Certain components used in existing products, as well
as products under development, are frequently purchased from single sources.
The company believes that alternative sources for such components may generally
be obtained when necessary, although the need to change suppliers or to
alternate between suppliers might cause material delays in delivery or
significantly increase costs. Moreover, there can be no assurance that the
company will be able to timely obtain components from alternate sources and on
commercially reasonable terms, if at all, and that the company would not suffer
a material adverse effect as a result.
Manufacturing and Operating Risks--The company's success is dependent upon
establishing appropriate manufacturing processes, resolving supply issues,
obtaining adequate manufacturing resources, and being able to contain
manufacturing costs.
The scope of the product lines offered by the company and the need for
product customization require a number of separate manufacturing processes and
components and significant management and engineering time and expertise.
Additionally, as the company develops new products, it will be required to
refine the prototypes of these products and develop new processes to
manufacture these products in commercial quantities. The company has
encountered and may continue to encounter difficulties involving inventory
supply, length of production cycles and shortages of manufacturing personnel.
Due to the shifting demand for the company's products and the high fixed costs
associated with manufacturing these products, the company may encounter
difficulty managing its operating costs. There can be no assurance that the
company will be able to reliably or efficiently manufacture its existing or new
products at commercially reasonable costs on a timely basis, if at all. Failure
to effectively manage the development and manufacture of its products could
adversely affect the company.
Product Liability, Market Withdrawal, and Product Recalls--Potential product
defects or related performance or safety issues might result in product
recalls, loss of market share and significant legal or insurance costs.
The company's business exposes it to potential product liability claims which
are inherent in the manufacture and sale of medical devices and, as such, the
company may face substantial liability to patients for damages resulting from
the faulty design or manufacture of products. The company has been a defendant
from time to time in product liability actions. The company maintains product
liability insurance with coverage limits of $5 million per occurrence and per
year in the aggregate. There can be no assurance that product liability claims
will not exceed coverage limits or that such insurance will continue to be
available at commercially reasonable rates, if at all. Consequently, a product
liability claim or other claim in excess of insured liabilities or with respect
to uninsured liabilities could have a material adverse effect on the company.
Complex medical devices, such as the company's products, can experience
performance problems in the field that require review and possible corrective
action by the manufacturer. The company periodically receives reports from
users of its products relating to performance difficulties they have
encountered. These or future product problems could result in market
withdrawals or product recalls, which could have a material adverse affect on
the company's business, financial condition and results of operations.
Patents and Intellectual Property--Patents, trademarks, and confidentiality
agreements could be ineffective in protecting the company's proprietary
information.
The company seeks to protect its proprietary rights through a combination of
technical experience, patent, trade secret and trademark protection and
nondisclosure agreements. The company's future success will depend in part on
its ability to obtain and enforce patent protection for its products and
processes, preserve its trade secrets and operate without infringing on the
patent or proprietary rights of others. The company's issued patents cover,
among other things, certain features of its Mammotest stereotactic breast
biopsy system, its SenoScan digital mammography system, and its MR biopsy
system.
18
<PAGE>
The company has numerous U.S. and foreign issued patents and pending patent
applications covering various aspects of its products. There can be no
assurance, however, that the company's current or future patents will not be
challenged, invalidated or circumvented, or that the rights thereunder will
provide the company with significant competitive advantages. In addition, the
laws of some foreign countries do not protect proprietary rights to the same
extent as the laws of the United States. The company anticipates that any
attempt to enforce its patents would be time consuming and costly. In addition,
the company could be found to have infringed on patents of others and, as a
result, could be required to alter its products or processes or acquire
licensing rights. Such rights might not be available on commercially reasonable
terms, if at all, requiring the company to cease making and selling any
infringing products and pay damages for past infringement.
The company also relies on trade secrets and proprietary know-how that it
seeks to protect, in part, through appropriate confidentiality and proprietary
information agreements. These agreements generally provide that all
confidential information developed or made known to an individual during the
course of his or her relationship with the company is not to be disclosed to
third parties, except in specific circumstances. They also generally provide
that all inventions conceived by the individual in the course his or her
services to the company are the company's exclusive property. There can be no
assurance that confidentiality or proprietary information agreements will not
be breached, that remedies for any breach would be adequate, or that the
company's trade secrets will not otherwise become known to, or independently
developed by, competitors.
The company from time to time has technology license agreements under which
it pays nominal royalties in connection with the sale of products using a third
party's technology.
In connection with the June 1995 sale of Series D Convertible Preferred Stock
to GE Medical Systems, the company granted contingent access to the technology
of, and rights to manufacture, an OEM product. On March 29, 1999, the company
announced an agreement to transfer to GE Medical Systems non-exclusive rights
to manufacture this OEM product, in exchange for 826,666 or 62% of the
1,333,333 shares of Series D Convertible Preferred Stock currently owned by GE
Medical Systems. Completion of the necessary technology transfer is required by
mid-April, 1999. See also related discussion at "Item 5-Market for Registrant's
Common Equity and Related Stockholder Matters--Risks Associated with Shares
Eligible for Future Sale" later in this report. See also "--Strategic
Alliances" for a discussion of potential license rights granted to Ethicon
Endo-Surgery.
As described more fully under Item 3 "Legal Proceedings," the company
continues to vigorously pursue its claims of patent infringement against Lorad
covering certain features of the company's stereotactic breast biopsy system.
Fischer(R), Fischer Imaging(R), Mammotest(R), EPIC(R), Mammovision(R), and
TRAUMEX(R) are registered trademarks of the company, and Mammotest Plus(TM),
Mammotest Plus "S"(TM), Mammovision Plus(TM), MammoSound(TM), HFX(TM), HFX
Plus(TM), SENOSCAN(TM), Cardiac CX/Pegasus(TM),Target on Scout(TM), EPACE(TM),
and EP/Stim(TM), EP/X(TM), and EP/X2(TM) are trademarks of the company.
Employees
As of December 31, 1998, the company had 408 employees, including 202 in
manufacturing, 61 in engineering, 113 in sales, marketing and service and 32 in
administration. None of the company's employees are parties to a collective
bargaining agreement. The company considers relations with its employees to be
satisfactory.
Risk of Dependence on Key Personnel--The departure of Mr. Nields or other key
employees could adversely affect the company's future success.
The company's future performance is partially dependent on the services of
Morgan W. Nields, the company's Chairman, Chief Executive Officer and largest
common stockholder. The company has no employment agreement with Mr. Nields
nor, typically, with other executives. The company carries $5 million of
19
<PAGE>
key man life insurance on Mr. Nields. In addition, the continued success of the
company will depend heavily on its ability to attract and retain highly
qualified engineering, management, manufacturing, marketing and sales
personnel. There can be no assurance that the company will be able to continue
to attract and retain such people. Failure to hire and retain such personnel
could have a material adverse effect on the company.
Other Developments
During the third quarter of 1997, the company decided to close its Addison,
Illinois manufacturing facility and, accordingly, recorded a $2.9 million
restructuring provision for the anticipated shortfall between required lease
payments and estimated sublease payments during the facility's remaining lease
term (running through June 2002), estimated facility closing costs, severance
and certain other non-recurring costs associated with this decision. In January
1999, the company fulfilled its remaining obligations for this facility by
agreeing to a $1.0 million lease buyout, completing the Addison closure within
the original $2.9 million provision.
Medical Advisory Board
The company maintains a Medical Advisory Board to provide advice to the
company with respect to new developments in the medical field. The company
seeks the advice of its Medical Advisory Board members for opinions on the
relative importance of new techniques in medicine, as well as the impact of new
and developing procedures on the company, particularly in the fields of
radiology and cardiology. From time to time, members of this board or their
institutions may purchase products from the company. Members receive no
compensation from the company other than reimbursement of expenses and nominal
honoraria. One of the Medical Advisory Board members, David G. Bragg, M.D., is
also a director of the company:
<TABLE>
<CAPTION>
Member Affiliation
------ -----------
<C> <S>
David G. Bragg, M. D. .............. Professor Emeritus and Former Chairman,
Radiology University of Utah School of
Medicine
Salt Lake City, Utah
Special Assistant to the Director,
Diagnostic Imaging Program
National Cancer Institute
Bethesda, Maryland
Joseph P. Galichia, M. D. .......... Galichia Cardiovascular Cardiology
Group P. A.
Wichita, Kansas
William R. Hendee, Ph. D. .......... Senior Associate Dean for Research
Medical College of Wisconsin
Milwaukee, Wisconsin
Philip Z. Israel, M. D.............. Member of the staff,
Breast Center,
Marietta, Georgia
Spencer B. King, M. D. ............. Director of Interventional Cardiology
Emory Hospital
Atlanta, Georgia
David S. Robinson, M. D............. Associate Professor
St. Luke's Hospital of Kansas City
Kansas City, Missouri
Wende Logan-Young, M. D............. Breast Clinic of Rochester
Rochester, New York
William M. Thompson, M. D........... Professor and Chairman of Radiology
University of Minnesota
Minneapolis, Minnesota
</TABLE>
20
<PAGE>
ITEM 2. PROPERTIES
The company maintains leased office and manufacturing facilities in Denver,
Colorado. This facility includes approximately 125,000 square feet of office
and manufacturing space and are leased from a partnership whose general
partners are Morgan W. Nields, the company's Chairman of the Board and Chief
Executive Officer, and Kinney L. Johnson, a member of the company's Board of
Directors. The Denver facilities include the company's headquarters. The
company also leases office space in Denmark, Germany, Australia and China. The
company believes its present facilities can accommodate several years of
growth.
In January 1999, the company completed the closure of its Addison
manufacturing facility. See also Item 1, "Other Developments".
ITEM 3. LEGAL PROCEEDINGS
The company is a defendant in various lawsuits incident to the operation of
its business. In addition, the company may from time to time be engaged in
litigation or other legal proceedings concerning disputes with its OEM
customers. Management believes that there are no pending legal proceedings that
would have a material adverse effect on the company's consolidated financial
position.
In April 1992, the company filed a patent infringement lawsuit against Lorad,
now owned by Trex Medical, in the United States District Court for the District
of Colorado. The company owns patent No. 5,078,142, covering certain features
of its Mammotest stereotactic breast biopsy system and believes that Lorad has
infringed certain claims of its patent with the introduction of its
mammographic biopsy system. In April 1998, following receipt of patent No.
5,735,264, the company filed a second patent suit against Trex Medical, also in
U. S. District Court for the District of Colorado. In July 1998, the U.S.
District Court granted the company's Motion to Consolidate the two patent
infringement suits. The consolidated suit seeks seeks to enjoin Lorad and its
agents from the manufacture, use and sale of the allegedly infringing
stereotactic breast biopsy system. The company is also seeking treble damages
and attorney's fees. Pre-trial discovery and deposition activity is now nearing
completion. The company expects a final pre-trial conference to occur in the
Summer of 1999, and that a late 1999 trial date may be set at that time.
The company is party to a lawsuit, as guarantor of work performed by a now-
bankrupt dealer in the United Kingdom. Damages and legal fees totaling
approximately $1.5 million are being sought for allegedly deficient pre-
installation site review and installation work. The trial ended on February 25,
1999. It is expected that a judgement will be rendered by early April 1999.
Based on a review of the evidence and testimony presented at trial, Management
believes that a loss contingency accrual of $0.5 million is warranted.
The company has received notice from the holder of a U.S. patent alleging
infringement by certain of the company's products and offering the company a
license to use the patent on terms that are not acceptable to the company. The
company believes that only one former product and one current product could
potentially be implicated by the patent. Based on the foregoing, the company
believes that, if required to take a license to the patent, any license fees
payable would not have a material adverse effect on the company's financial
position.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Not Applicable.
21
<PAGE>
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
The company's Common Stock trades on the Nasdaq Stock Market under the symbol
"FIMG". The following table sets forth, for each of the periods indicated, the
high and low closing sale prices per share of the Common Stock as reported by
the Nasdaq Stock Market.
<TABLE>
<CAPTION>
High Low
----- -----
<S> <C> <C>
1997
First Quarter.................................................... $7.75 $5.00
Second Quarter................................................... 7.88 3.25
Third Quarter.................................................... 8.00 5.63
Fourth Quarter................................................... 6.25 4.81
1998
First Quarter.................................................... $5.63 $3.63
Second Quarter................................................... 5.00 3.31
Third Quarter.................................................... 4.44 2.25
Fourth Quarter................................................... 3.13 1.91
</TABLE>
As of March 1, 1999, there were about 230 recordholders of the company's
Common Stock. The company believes that it has in excess of 1,500 beneficial
owners.
The company has not paid any cash dividends on its Common Stock and intends
to retain future earnings to finance the growth of the company's business
rather than to pay cash dividends. The company is subject to restrictions on
the paying of dividends under terms of its revolving credit agreement and under
state law.
Risk of Price Volatility of Common Stock--Significant fluctuations in the
company's quarterly operating performance or in stock market performance
generally could cause the price of the company's Common Stock to be highly
volatile.
The market price of the Common Stock could be subject to significant
fluctuations in response to variations in quarterly operating results and other
factors. In addition, the securities markets have experienced significant price
and volume fluctuations from time to time in recent years that have often been
unrelated or disproportionate to the operating performance of particular
companies. These broad fluctuations may adversely affect the market price of
the Common Stock.
Risks of Fluctuations in Quarterly Results of Operations--Various factors
indentified in this report are likely to continue to cause significant
fluctuations in operating results.
The company has experienced fluctuations in its quarterly operating results
and anticipates that such fluctuations will continue and could intensify.
Factors giving rise to fluctuations in operating results include, but are not
necessarily limited to, those identified in the "Overview" section of
Management's Discussion and Analysis of Financial Condition and Results of
Operations included elsewhere in this Form 10-K. Fluctuations in operating
results may result in volatility in the price of the Common Stock. Although the
company has taken significant steps to return to profitability, there can be no
assurance that profitability will be achieved or, if achieved, that levels of
profitability will not vary significantly between quarters.
Based on the foregoing, the company believes that future revenues, expenses,
and operating results are likely to vary significantly from quarter to quarter.
As a result, quarter-to-quarter comparisons of operating results are not
necessarily meaningful or indicative of future performance. Further, it is
likely that, from time to time, the company's future quarterly operating
results will be below the expectations of public market analysts or
22
<PAGE>
investors. In such event, or in the event that adverse medical device market
conditions prevail, or are perceived to prevail, with respect to the company's
business or generally, the market price of the company's Common Stock would
likely be materially adversely affected.
RISKS ASSOCIATED WITH SHARES ELIGIBLE FOR FUTURE SALE--CONVERSION OF THE
CONVERTIBLE PREFERRED STOCK HELD BY G.E. MEDICAL, EXERCISES OF A SIGNIFICANT
NUMBER OF STOCK OPTIONS, OR OTHER SUBSTANTIAL SALES OF COMMON STOCK COULD
ADVERSELY EFFECT THE MARKET PRICE OF COMMON STOCK.
Sales of a substantial number of shares of Common Stock, or the perception
that such sales could occur, could have a material adverse effect on the
market price of the company's Common Stock and could impair its ability to
raise capital through the sale of equity securities. As of March 1, 1999 there
were approximately 7,029,000 shares of Common Stock outstanding, and there
were 829,000 shares reserved for issuance upon exercise of outstanding stock
options, 415,000 of which were then exercisable. Additionally, 1,333,333
shares of the company's Series D Convertible Preferred Stock ("Convertible
Preferred Stock"), which are convertible at any time into an equivalent number
of shares of Common Stock, are outstanding. After the company consummates its
agreement with General Electric Company, announced March 29, 1999, to give GE
Medical Systems a non-exclusive right to manufacture the Tilt-C system, in
exchange for 826,666 or 62% of the 1,333,333 shares of Convertible Preferred
Stock currently owned by GE Medical Systems, 506,667 shares of Convertible
Preferred Stock would remain outstanding. GE Medical Systems, the holder of
the Convertible Preferred Stock, has certain demand registration rights with
respect to this stock, as well as certain piggyback registration rights.
Future sales of shares of Common Stock under Rule 144 of the Securities Act
by existing stockholders of Common Stock (through the exercise of registration
rights or otherwise) or through the issuance of shares of Common Stock upon
the exercise of options or otherwise could have an adverse effect on the price
of the Common Stock.
RISKS ASSOCIATED WITH CONTROL BY MANAGEMENT AND CERTAIN STOCKHOLDERS--POLICIES
OF THE COMPANY COULD BE SIGNIFICANTLY INFLUENCED BY THE VOTING POWER OF THE
COMPANY'S OFFICERS, DIRECTORS, AND SIGNIFICANT SHAREHOLDERS.
The company's officers and directors beneficially own, in the aggregate,
approximately 1,275,000 shares, or 18%, of the company's Common Stock as of
March 1, 1999. As a result, the officers and directors are able to exercise
significant influence on the election of the company's Board of Directors and
thereby direct the policies of the company.
Additionally, GE Medical Systems owns 1,333,333 shares of the company's
Convertible Preferred Stock that is convertible at any time, at the option of
the holder, into an equivalent number of shares of Common Stock. Although the
Convertible Preferred Stock is non-voting, except as required by law, if GE
Medical Systems were to convert the Convertible Preferred Stock into Common
Stock, it would own approximately 16% of the company's outstanding stock. GE
Medical Systems would therefore be able to significantly influence the
policies of the company. In the event the company consummates its agreement
with General Electric Company, announced March 29, 1999, the remaining 506,667
shares of Convertible Preferred Stock, if converted, would constitute
approximately 6.7% of the company's outstanding stock, potentially reducing
the ability of GE Medical Systems to influence the company.
CERTAIN ANTI-TAKEOVER EFFECTS--CERTAIN TERMS OF THE COMPANY'S CHARTER AND
OTHER AGREEMENTS, AND THE CONCENTRATION OF SHARE OWNERSHIP, COULD DISCOURAGE
PURCHASES OF OR OFFERS TO PURCHASE THE COMPANY, EVEN IF FAVORABLE TO
STOCKHOLDERS.
The company's Certificate of Incorporation and Bylaws include provisions
that may be deemed to have anti-takeover effects and may delay, defer or
prevent a takeover attempt that stockholders might consider in their best
interests. These provisions include the ability of the Board of Directors to
issue shares of preferred stock in
23
<PAGE>
one or more series with such rights, obligations and preferences as the Board
of Directors may provide, a "fair price" provision, a provision that requires
stockholder action to be taken at meetings and not by written consent, a
provision under which only the Board of Directors may call meetings of
stockholders, certain advance notice procedures for nominating candidates for
election to the Board of Directors and staggered terms for its Board of
Directors.
In November 1994, the company's Board of Directors adopted a stockholder
rights plan and, pursuant thereto, issued preferred stock purchase rights
("Rights") to the holders of its common stock. The Rights have certain anti-
takeover effects. If triggered, the Rights would cause substantial dilution to
a person or group of persons (other than certain exempt persons, including
Morgan W. Nields, one of the company's founders and its Chairman of the Board
and Chief Executive Officer, Kinney L. Johnson, one of the company's founders
and a director, and GE Medical Systems) who acquires more than 15% of the
Common Stock on terms not approved by the Board of Directors. Additionally, in
connection with the company's sale of Convertible Preferred Stock to GE
Medical Systems in June 1995, GE Medical Systems has the right to convert the
Convertible Preferred Stock for 1,333,333 shares of Common Stock, which would
then equal approximately 16% of the company's outstanding Common Stock. In
connection with this transaction, GE Medical Systems also received certain
contingent rights, including rights to use a manufacturing license for the
company's Tilt-C technology, in return for cancellation of the Convertible
Preferred Stock upon a change of control of the company or certain other
events. Pursuant to an agreement between the company and General Electric
Company announced March 29, 1999, GE Medical Systems would acquire non-
exclusive Tilt-C manufacturing rights in exchange for 826,666 or 62% of the
1,333,333 shares of Convertible Preferred Stock currently owned by GE Medical
Systems. If this agreement is concluded, the remaining 506,667 shares of
Convertible Preferred Stock, if converted, would constitute approximately 6.7%
of the company's outstanding stock. In any event, the Rights, and the shares
of Convertible Preferred Stock owned by GE Medical Systems could discourage or
make more difficult a tender offer, acquisition, merger or other similar
transaction, even if favorable to the company's stockholders. See Note 12
"Commitments and Contingencies", of Notes to Consolidated Financial Statements
for information regarding the company's Retention Bonus Plan.
24
<PAGE>
ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA
The following table contains certain selected consolidated financial data and
is qualified by the detailed Consolidated Financial Statements and Notes
thereto included elsewhere in this Form 10-K. The consolidated balance sheet
data as of December 31, 1998 and 1997 and the consolidated statement of
operations data for each of the three years in the period ended December 31,
1998 have been derived from the company's Consolidated Financial Statements,
which have been audited by Arthur Andersen LLP, independent public accountants,
as indicated in their report included elsewhere herein. The consolidated
balance sheet data as of December 31, 1996, 1995 and 1994 and the consolidated
statement of operations data for both of the two years in the period ended
December 31, 1995 are derived from the company's Consolidated Financial
Statements which have been audited by Arthur Andersen LLP, independent public
accountants, as indicated in their reports, which statements are not included
herein.
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
--------------------------------------------
1998 1997 1996 1995 1994
------- -------- ------- ------- -------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Revenues........................ $59,804 $ 56,908 $77,508 $76,750 $68,473
Cost of sales................... 36,883 39,252 47,073 46,905 44,526
------- -------- ------- ------- -------
Gross profit.................. 22,921 17,656 30,435 29,845 23,947
------- -------- ------- ------- -------
Operating expenses:
Research and development...... 6,394 6,043 6,746 6,690 5,595
Selling, marketing and serv-
ice.......................... 15,299 16,323 18,776 15,461 15,573
General and administrative.... 5,284 4,988 4,863 4,800 4,697
Litigation loss............... 500 -- -- -- --
Restructuring provisions...... -- 2,900 -- -- 2,419
------- -------- ------- ------- -------
Total operating expenses.... 27,477 30,254 30,385 26,951 28,284
------- -------- ------- ------- -------
(Loss) earnings from opera-
tions.......................... (4,556) (12,598) 50 2,894 (4,337)
Interest expense................ (357) (181) (595) (678) (1,247)
Interest income................. 74 271 138 62 15
Other income (expense), net..... 38 (760) (163) (1) (71)
------- -------- ------- ------- -------
(Loss) earnings before income
taxes.......................... (4,801) (13,268) (570) 2,277 (5,640)
Provision (benefit) for income
taxes.......................... 2,002 -- (209) -- --
------- -------- ------- ------- -------
Net (loss) earnings............. $(6,803) $(13,268) $ (361) $ 2,277 $(5,640)
======= ======== ======= ======= =======
Net (loss) earnings per common
share
Basic......................... $ (.97) $ (1.91) $ (.06) $ .41 $ (1.02)
======= ======== ======= ======= =======
Diluted....................... $ (.97) $ (1.91) $ (.06) $ .36 $ (1.02)
======= ======== ======= ======= =======
Shares used to calculate (loss)
earnings per share
Basic......................... 6,980 6,949 6,299 5,561 5,526
======= ======== ======= ======= =======
Diluted....................... 6,980 6,949 6,299 6,331 5,526
======= ======== ======= ======= =======
BALANCE SHEET DATA (AT END OF
PERIOD):
Working capital................. $19,095 $ 25,179 $36,187 $23,635 $12,057
Total assets.................... 50,969 49,144 60,432 55,650 46,889
Total debt...................... 7,425 533 432 4,722 9,441
Total stockholders' investment.. 28,430 35,185 47,805 33,584 21,643
</TABLE>
25
<PAGE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Forward-looking Statements and Risks of Investing in the Company
The following discussion of the results of operations and financial condition
should be read in conjunction with the company's Consolidated Financial
Statements and Notes thereto appearing elsewhere in this Form 10-K. This Form
10-K, including information incorporated by reference herein, contains forward-
looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. For this purpose, statements that are not statements of historical
fact may be deemed to be forward-looking statements. Without limiting the
foregoing, the words "believes", "expects", "anticipates", "plans",
"estimates", and similar words and expressions are intended to identify such
statements. These forward-looking statements include statements about:
. resolutions of deficiencies noted by the FDA,
. the adequacy of financial resources,
. future operating results including revenues and expenses,
. sales under the company's strategic alliances, OEM agreements and
otherwise, including marketing arrangements for Mammotest and other
products,
. the status of SenoScan and other new products in development,
. the size and growth of the company's markets,
. the effectiveness of efforts to transfer production activities from the
company's Addison, Illinois manufacturing facility,
. the success of efforts to reduce manufacturing and other costs,
. manufacturing capacity and capabilities,
. submissions to the FDA and receipt of FDA approvals and clearances,
. the company's assessment of costs of modifications required to become
Year 2000 compliant,
. availability of raw materials and components, and
. other matters.
These forward-looking statements involve risks and uncertainties. The actual
results that the company achieves may differ materially from those discussed in
such forward-looking statements due to the risks and uncertainties described in
the risks of investing in the company set forth (i) in the Business section of
this Form 10-K under the headings:
"Risks Associated with OEM Agreements," "Sales and Marketing,"
"International Operations," "Strategic Alliances", "Risks of Technological
Change and New Products," "Risks of New Product Development and Market
Acceptance," "Competition," "Government Regulation," "Government
Reimbursement," "Manufacturing and Operating Risks," "Product Liability,
Market Withdrawal, and Product Recalls," "Patents and Intellectual
Property," "Risk of Dependence on Key Personnel," in the Market for
Registrant's Common Equity and Related Stockholder Matters under the
headings "Risk of Price Volatility of Common Stock," "Risks of Fluctuations
in Quarterly Results of Operations," "Risks of Fluctuations in Quarterly
Results of Operations," "Risks Associated with Shares Eligible for Future
Sale," "Risks Associated with Control by Management and Certain
Stockholders," and "Certain Anti-Takeover Effects,"
(ii) in the Management's Discussion and Analysis of Financial Condition and
Results of Operations ("MD&A") section under the "Overview," "Year 2000
Update," "Quantitative and Qualitative Disclosures About Market Risk," "FDA
Regulation," and "Recent Developments" headings, (iii) elsewhere in the
Business, MD&A, and other sections of this Form 10-K, and (iv) in the company's
Quarterly Reports on Form 10-Q.
26
<PAGE>
Overview
Risk of Continued Losses
The company designs, manufactures and markets specialty and general purpose
medical imaging systems for the diagnosis and treatment of disease. The
company's newer products are directed towards medical specialties, such as
diagnosing and treating breast cancer, heart disease and vascular disease, in
which image-guided, minimally invasive therapies are replacing open surgical
procedures. The company also designs and manufactures specialty x-ray imaging
components and subsystems for several leading medical product companies and
sells general radiology systems for use in hospitals, clinics and physicians'
offices.
The company has experienced significant losses in four of the five years
ended December 31, 1998. Although the company was profitable in 1995 and for
the first nine months of 1996, significant losses have been incurred since that
time. Significant factors giving rise to recent losses include excessive
manufacturing capacity and related costs to manufacture, intense competition
for certain of the company's products, declining margins and demand for OEM
products, and a general slowdown in capital expenditures by hospitals. The
company cannot predict when it will return to profitability, although it has
taken significant steps to reduce costs and improve sales. These include:
. entering into a distribution partnership, in October 1997, with Ethicon
Endo-Surgery for the marketing and sale of Mammotest breast biopsy
systems,
. entering into a strategic alliance with Direct Radigraphy Corp., a
subsidiary of Sterling Diagnostics, Inc. (See the "Strategic Alliances"
heading of the Business Section of this Form 10-K),
. closure of the company's Addison, Illinois manufacturing facility, and
. other actions to reduce operating expenses and manufacturing costs.
Improvement in the company's results of operations will depend on many
factors, including:
. demand for the company's products,
. the availability of adequate financial resources,
. the company's ability to maintain or increase gross margins,
. the effectiveness of efforts to control manufacturing and other costs,
. effective negotiation and implementation of distribution arrangements for
Mammotest and other products,
. effective implementation of marketing and sales strategies in the United
States and internationally,
. maintenance or renewal of orders under OEM agreements with favorable
terms, and
. the development and introduction of new products that compete
successfully.
The company believes that improved factory utilization is a key factor in
returning to acceptable levels of profitability. Therefore, the company decided
in the third quarter of 1997 to close its Addison, Illinois manufacturing
facility and outsource or transfer Addison production. In January 1999, the
company fulfilled its remaining obligations for this facility by agreeing to a
$1.0 million lease buyout, completing the Addison closure within the original
$2.9 million provision.
The company expects continued significant quarterly and annual fluctuations
in revenues, operating results and net income, depending on such factors as:
. delays in development projects,
. the timing of orders for large system products and products produced
under OEM contracts, and related manufacturing and shipment scheduling,
27
<PAGE>
. new product introductions or marketing initiatives by the company or its
competitors,
. the effects of managed healthcare on capital expenditures and
reimbursement,
. increases in marketing, research, and other costs in relation to sales,
. regulatory clearance of new products,
. the effect of general economic conditions of the company's markets, and
. the effects of seasonal patterns and other timing issues with respect to
customer purchasing decisions.
Because the timing of the occurrence of such factors is difficult to
anticipate and many of the company's costs are fixed, the company may not be
able to sufficiently reduce its costs in periods when its revenues are less
than anticipated and may suffer unexpected losses or lower income in these
periods.
In recent years, the company has attempted to expand its international sales
and marketing efforts, which have resulted in losses from its international
operations. The company can expect to continue to incur losses until
international revenues reach sufficient levels. Additionally, the company's
exposure to foreign currency and other international business risk may increase
as its international business grows. The company attempts to minimize these
risks by: (i) generally requiring payments in U.S. dollars, (ii) using letters
of credit, and (iii) requiring advance deposits and through other means. There
can be no assurance, however, international sales efforts will be successful or
that associated risks can be minimized. International revenues declined
substantially in 1998 and 1997.
Sales of the company's Mammotest breast biopsy systems were lower in 1997 as
compared to 1996, but increased in 1998. Beginning in the second half of 1996,
the company faced aggressive and successful competition within the surgical
stereotactic core needle breast biopsy market from U. S. Surgical. The
company's October 1997 marketing partnership with Ethicon Endo-Surgery was
intended to more adequately address this market. In December 1998, following
its acquisition by Tyco Corporation, U. S. Surgical terminated its OEM
agreement with Trex. While long-term competitive conditions may become more
favorable to the company, it is uncertain whether the near-term impact on
Mammotest sales will be favorable or unfavorable.
In late 1997, the company entered into an alliance with Direct Radiographic
Corp., a subsidiary of Sterling Diagnostic Imaging, Inc., under which the
company will develop specific digital radiographic systems, utilizing
Sterling's DirectRay(TM) digital image detector technology. Six prototypes for
the first product, a dedicated digital chest system, have been installed with
encouraging results. In January 1999, the Agfa-Gevaert Group announced the
acquisition of Direct Radiography's parent company. The Direct Radiography is
not included in this acquisition. In order to continue product and market
development, Direct Radiography must obtain alternative financial sponsorship.
There can be no assurance given, at this time, that such sponsorship can be
obtained.
Year 2000 Update
General
The company uses software and related technologies in its products and in
product development and manufacturing that may be impacted by the Year 2000.
The Year 2000 issue exists because many computer systems and applications use
two-digit date fields to designate a year. As a result, date-sensitive systems
may recognize the Year 2000 as 1900, or not at all. This inability to properly
treat the Year 2000 could cause systems to process critical financial and
operational information incorrectly.
28
<PAGE>
Year 2000 Project
The company is in the process of evaluating its products, computer hardware,
and operating software, and third party suppliers for possible Year 2000
problems. This project is organized as follows:
<TABLE>
<CAPTION>
Anticipated Anticipated
Completion Out-of-Pocket
Area Task/Status Date Cost
---- ----------- ------------ --------------
<S> <C> <C> <C> <C>
I. Products:
Current versions................ Initial review Complete *
Documentation Complete *
Earlier versions................ Develop evaluation/testing program Complete *
Perform testing Complete *
Documentation Complete *
Develop remedial program, if necessary 2nd qtr 1999 *
II. Primary business software:
Upgrade to Year 2000 compliant
version Complete Under $25,000
Perform testing Complete *
Provide user training Complete *
Update customized reporting/features Complete *
III. Other software applications:
Major payroll and engineering
applications................... Obtain certification of Year 2000
compliance Complete
Other applications.............. Evaluate and/or obtain certifications 3rd qtr 1999 *
IV. Hardware:
Networks........................ Confirm Year 2000 compliance Complete *
Personal computers.............. Confirm Year 2000 compliance Complete *
Replace or upgrade as necessary 2nd qtr 1999 Under $100,000
V. Third party suppliers:
Establish evaluation criteria Complete *
Survey suppliers 2nd qtr 1999 *
Re-source as necessary 3rd qtr 1999 *
</TABLE>
- --------
*No significant out-of-pockets incurred or expected to be incurred.
At this time, the company has not formulated contingency plans in the event
that systems are not Year 2000 compliant. The need to develop such plans will
be assessed following the completion of testing of its primary business
software and upon receipt of information from critical third party suppliers
regarding their Year 2000 compliance.
Costs
The cost to be incurred in conjunction with the Year 2000 project is expected
to be less than $200,000, for anticipated upgrades to existing desk-top
personal computers and for the assistance of outside consultants in upgrading
the company's primary business system. This amount is not considered material
to the company's financial position. Unanticipated problems could cause this
amount to be exceeded, however, and no assurance can be given that, under such
circumstances, the amount would not be material.
It is anticipated that most Year 2000 Project activities will be performed
with internal resources. Consequently, Year 2000 activities can be anticipated
to continue to delay other projects, particularly in the area of new
information systems development. Such delays are not, however, expected to
materially impact the company's results of operations.
29
<PAGE>
Risks
The failure to correct a material Year 2000 problem could result in an
interruption in, or failure of, normal business activities or operations.
There is inherent uncertainty regarding the Year 2000 problem, in part
resulting from the uncertainty of the Year 2000 readiness of third-party
suppliers and customers. Therefore, the company is unable to predict with
certainty whether the consequences of Year 2000 failures will have a material
impact on the company's results of operations, liquidity or financial
condition. The Year 2000 Project is expected to significantly reduce the
company's level of uncertainty about the Year 2000 problem, in particular,
with respect to the Year 2000 compliance and readiness of its third-party
suppliers. The company believes that the possibility of significant
interruptions of normal operations should be significantly reduced by the
implementation of upgraded business systems and the completion of the Year
2000 project as scheduled.
Based on its assessment to date, the company believes that few of its
current products will be affected by the Year 2000 problem. Of those that may
be affected, the only significant risk appears to be the possible inaccurate
dating of patient records. The remedial actions to correct dating problems
that may occur appear to be either:
i. the customer being able to reset the date (on a one-time basis) to
prevent future occurrences or
ii. implementation of modifications currently under development by the
company or third-party suppliers, which are expected to be finalized and
released to customers by the end of the first quarter of 1999.
The company is nearing completion of its evaluation of earlier versions of
current products and may conclude that problems less easily addressed do
exist. If such problems are identified, disruption of customers' operations
could conceivably occur, potentially resulting in legal actions being taken
against the company, even though Year 2000 problems are not expressly covered
by product warranties.
Readers are cautioned that forward-looking statements contained in the Year
2000 Update should be read in conjunction with the company's cautionary
statement regarding forward-looking statements elsewhere in this Form 10-K,
which is provided under the "Safe Harbor" provisions of the Private Securities
Litigation Reform Act of 1995.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Market risk represents the risk of loss that may impact the financial
position, results of operations or cash flows of the company due to adverse
changes in financial and commodity market prices and rates. The company is
exposed to market risk in the areas of changes in United States interest rates
and changes in foreign currency exchange rates as measured against the United
States dollar. These exposures are directly related to its normal operating
and funding activities. Historically and as of December 31, 1998, the company
has not used derivative instruments or engaged in hedging activities.
Interest Rate Risk
The interest payable on the company's revolving line of credit is variable
based on the prime rate and, is therefore, affected by changes in market
interest rates. At December 31, 1998, approximately $6.6 million was
outstanding with an interest rate of 9.25% (prime plus 1%). The line of credit
is cancelable upon 30 days notice by the lender and, should such cancellation
occur, or the company's liquidity needs exceed amounts available under this
line of credit, the interest rate applicable to replacement credit facilities
might be significantly higher. For example, if the interest rate on the
company's line of credit had been twice the rates in effect for its year ended
December 31, 1998, the company would have incurred additional interest expense
of approximately $350,000 for the year, with an associated $.05 increase in
the per share loss for that year. The company attempts to manage its interest
rate risk by monitoring interest rates which are available under other types
of lending instruments and through other lenders but, at present, does not
qualify for lending instruments which would not be more expensive that its
current month-to-month lending arrangement. Therefore, the company's exposure
to changes in interest rates will be significant until such time as its
operating results permit it greater access to other lenders and lending
instruments on terms equivalent or superior to those available under its
current lending agreement.
30
<PAGE>
Foreign Currency Risk
The company has a wholly-owned subsidiary in Australia and a 90% owned
subsidiary in Denmark which, in turn, owns subsidiaries in Germany and France.
Local assets and liabilities, principally intercompany debt to the parent
company, are recorded in local currencies, thereby creating exposures to
changes in exchange rates. These changes may positively or negatively affect
the company's operating results. As disclosed at Note 10 to Notes to
Consolidated Financial Statements, revenues in foreign currency through all
foreign subsidiaries constituted approximately 2% of 1998 total revenues for
the company. The company therefore does not believe that foreseeable near-term
changes in exchange rates will have in a material effect on future earnings,
fair values or cash flows of the company and has chosen not to enter into
foreign currency hedging instruments. There can be no assurance that such an
approach will prove to have been successful, especially in the event of a
significant and sudden decline in the value of any of the applicable local
currencies.
FDA REGULATION
The company is subject to periodic inspections by the Food and Drug
Administration, whose primary purpose is to audit the company's compliance
with Good Manufacturing Practices, which include testing, quality control and
documentation procedures. In March 1995, the company's Denver facility
received a Warning Letter from the FDA concerning documentation and other
deficiencies. The company rectified these deficiencies and resolved the matter
with the FDA later that year. Following an inspection concluded in December
1996, the FDA issued Inspectional Observations Form 483 and a Warning Letter
regarding manufacturing practices at its Denver facility. The FDA requested a
written response to the Warning Letter regarding planned corrective actions
and a favorable third-party certification of the company's manufacturing and
quality systems. These actions were completed. In October 1998, following a
periodic inspection, the FDA issued a Form 483 regarding possible deficiencies
in manufacturing, quality, and documentation practices. The company has
submitted its response to the Form 483 and is instituting corrective actions.
The recent issuance of another Form 483 increases the possibility that one or
more of the sanctions described below could be imposed.
Failure to satisfy FDA requirements can result in the company's inability to
receive awards of federal government contracts, to receive new marketing or
export clearances for products manufactured at its Denver facility, or FDA
enforcement actions including, among other things, product seizure,
injunction, and/or criminal or civil proceedings being initiated by the FDA
without further notice. Although the company strives to operate within the
requirements imposed by the FDA, there can be no assurance that these
deficiencies can be corrected or that the company will be able to satisfy FDA
compliance concerns in the future. These ongoing FDA compliance reviews and/or
related delays in product clearances could have a material adverse effect on
the company.
31
<PAGE>
RESULTS OF OPERATIONS
The following table sets forth the percentage relationship to revenues
represented by certain data included in the company's statements of operations
for the years ended December 31:
<TABLE>
<CAPTION>
1998 1997 1996
----- ----- -----
<S> <C> <C> <C>
Revenues.................... 100.0 % 100.0 % 100.0 %
Cost of sales............... 61.7 69.0 60.7
----- ----- -----
Gross profit.............. 38.3 31.0 39.3
----- ----- -----
Operating expenses:
Research and development.. 10.7 10.6 8.7
Selling, marketing and
service.................. 25.6 28.7 24.2
General and administra-
tive..................... 8.8 8.8 6.3
Litigation loss........... 0.8 -- --
Restructuring provision... -- 5.1 --
----- ----- -----
Total operating ex-
penses................. 45.9 53.2 39.2
----- ----- -----
(Loss) earnings from opera-
tions...................... (7.6) (22.2) 0.1
Interest expense............ (0.6) (0.3) (0.8)
Interest income............. 0.1 0.5 0.2
Other income, net........... 0.1 (1.3) (0.2)
----- ----- -----
Loss before income taxes.... (8.0) (23.3) (0.7)
Provision (benefit) for in-
come taxes................. 3.3 0.0 (0.2)
----- ----- -----
Net loss.................... (11.3)% (23.3)% (0.5)%
===== ===== =====
</TABLE>
1998 COMPARED TO 1997
Revenues. Revenues increased from $56.9 million in 1997 to $59.8 million in
1998. The revenue increase was due to a 40% increase in shipments of Mammotest
and other mammography products and a significant increase in service revenues,
offset by declines in shipments of OEM and general radiology products. The
increase in mammography product sales was, in significant part, due to the
favorable effects of the company's marketing partnership with Ethicon Endo-
Surgery. See "--Overview." The decline in general radiology shipments was due
to shipment delays caused by the transfer of production of general radiology
products from the company's Addison, Illinois manufacturing facility, which is
now closed. The decline in OEM shipments is, in part, due to the company's
decision to de-emphasize low margin OEM business.
Gross Profit. Gross profit as a percentage of total revenues increased from
31.0% in 1997 to 38.3% in 1998. This increase was due to the favorable effects
of reducing fixed factory capacity costs, through the closure of the company's
Addison manufacturing facility, and to the shift in product mix to relatively
higher margin mammography and service business, from relatively lower margin
OEM product sales.
Research and Development Expenses. Research and development expenses were
$6.4 million, or 10.7% of total revenues, in 1998, as compared to $6.0
million, or 10.6% of total revenues, in 1997. The modest increase in research
and development expenses is primarily attributable to costs associated with
developing a digital general radiography system in conjunction with Sterling.
As a percentage of total revenues, research and development expenses are
essentially unchanged. The company is maintaining its commitment to research
and development as the key to its long-term success, with the development of
digital imaging products for mammography and general radiography a key focus
of the company's research and development activities.
Selling, Marketing and Service Expenses. Selling, marketing and service
expenses decreased to $15.3 million in 1998 as compared to $16.3 million in
1997. As a percentage of total revenues, selling, marketing and service
expenses decreased from 28.7% in 1997 to 25.6% in 1998. The decrease in
selling, marketing, and
32
<PAGE>
service expenses and the decrease as a percentage of total revenues are
primarily due to planned reductions in marketing expenditures, as strategic
marketing partners have assumed part of the cost of product marketing.
General and Administrative Expenses. General and administrative expenses
increased to $5.3 million in 1998 from $5.0 million in 1997. General and
administrative expenses equaled 8.8% of total revenues in both 1998 and 1997.
The increase in general and administrative expenses was due to higher legal
expenses in 1998 as compared to 1997, partly offset by cost savings associated
with continued efforts to reduce operating expenses. The increase in legal
expenses is primarily due to preparations for the company's patent
infringement lawsuit against Lorad, which is expected to commence during 1999.
(See Item 3, Legal Proceedings.)
Litigation Loss. The litigation loss of $0.5 million, or 0.8% of total
revenue, is the result of the company's guarantee of work performed by a now-
bankrupt dealer in the United Kingdom. (See Item 3, Legal Proceedings.)
Interest Expense. Interest expense increased to $0.4 million in 1998 from
$0.2 million in 1997. The increase in interest expense is primarily due to an
increase in borrowings under the company's line of credit beginning in mid-
1998. These borrowings were primarily used to fund increases in working
capital. See "Liquidity and Capital Resources."
Net Loss. The net loss declined from $13.3 million in 1997 to $6.8 million
in 1998. The decrease is primarily attributable to an increase in sales of
mammography product shipments and an increase in service revenues, both of
which are relatively high margin, and the favorable effects of the Addison
factory closure on manufacturing costs, partially offset by the $2.0 million
write off of deferred tax assets.
1997 COMPARED TO 1996
Revenues. Revenues decreased from $77.5 million in 1996 to $56.9 million in
1997. The revenue decrease was principally due to a decline in shipments of
OEM products, as well as declines in sales of general radiology, mammography,
and electrophysiology products. The decline in mammography product sales was
in part due to aggressive and successful competition within the surgical
stereotactic core needle biopsy market from U.S. Surgical Corporation. In an
effort to more adequately address this market, the company entered into a
marketing partnership with Ethicon Endo-Surgery. See "--Overview."
Gross Profit. Gross profit as a percentage of total revenues decreased from
39.3% in 1996 to 31.0% in 1997. This decrease was primarily due to the
unfavorable effects of reduced factory utilization and to significant one-time
manufacturing costs associated with the company's decision to close its
Addison, Illinois manufacturing facility. The company believes that such one-
time manufacturing costs were as much as $2.0 million in the fourth quarter of
1997, including about $1.2 million of non-cash inventory adjustments and $0.8
million of plant rearrangement, labor inefficiencies, and other out-of-pocket
cash expenses. Such costs do not include those included in the $2.9 million
restructuring charge recorded in 1997, principally for lease obligations and
employee severance costs.
Research and Development Expenses. Research and development expenses were
$6.0 million, or 10.6% of total revenues, in 1997, as compared to $6.7
million, or 8.7% of total revenues, in 1996. The reduction in research and
development expenses was primarily attributable to efforts to narrow the focus
of engineering efforts and eliminate marginal engineering efforts, as well as
efficiencies caused by the transfer of engineering activities from the
company's Addison, Illinois manufacturing facility. The increase in research
and development expenses as a percentage of total revenues was due to lower
revenues in 1997. The company is maintaining its commitment to research and
development as the key to its long-term success, with the development of
digital imaging products for mammography continuing to be a key focus of the
company's research and development activities.
Selling, Marketing and Service Expenses. Selling, marketing and service
expenses decreased to $16.3 million in 1997 as compared to $18.8 million in
1996. As a percentage of total revenues, selling, marketing and service
increased to 28.7% in 1997 from 24.2% in 1996. The decrease in selling,
marketing, and service
33
<PAGE>
expenses is primarily a result of decreased warranty, installation, and
commissions expenses caused by lower revenues in 1997, planned reductions in
the scope of marketing activities, and efficiencies in service-related
activities caused by the transfer of such activities from the company's
Addison, Illinois facility. As a percentage of revenues, selling, marketing,
and service expenses have increased due to the impact of fixed costs compared
against lower total revenue.
General and Administrative Expenses. General and administrative expenses
increased to $5.0 million in 1997 from $4.9 million in 1996. General and
administrative expenses equaled 8.8% and 6.3% of total revenues in 1997 and
1996, respectively. The modest increase in general and administrative expenses
was primarily due to higher legal expenses in 1997 as compared to 1996, partly
offset by cost savings associated with the closing of the company's Addison
facility. The increase in legal expenses is primarily due to preparations for
the company's patent infringement lawsuit against Lorad, which is expected to
commence during 1998. (See Item 3, Legal Proceedings.)
Interest Expense. Interest expense decreased to $0.2 million in 1997 from
$0.6 million in 1996. The decrease in interest expense is primarily due to the
elimination of borrowings under the company's line of credit beginning in mid-
1996 and extending throughout 1997. See "Liquidity and Capital Resources."
Net Loss. The net loss increased from $0.4 million in 1996 to $13.3 million
in 1997. The increased loss was primarily due to the unfavorable effects of
the company's decision to close its Addison, Illinois manufacturing facility,
which included a $2.9 million restructuring charge, an estimated $1.2 million
of non-cash inventory write-offs, and about $0.8 million of plant re-
arrangement and other out-of-pocket costs, as well as the effects of a
significant decline in revenues, primarily due to a decline in shipments of
OEM and mammography products.
INCOME TAXES
The company's effective tax rate was 42% and 0% in 1998 and 1997,
respectively. The 1998 and 1997 rates reflect increases of $3.4 million and
$4.4 million, respectively, in the valuation allowance against net deferred
tax assets. These increases are due mainly to uncertainty relating to the
realizability of net deferred tax assets due to the company's recent history
of net operating losses. At December 31, 1998, the company had valuation
allowances of approximately $8.8 million, reducing deferred tax assets to $0.
The realizability of net deferred tax assets is dependent on the company's
ability to generate future taxable income, and the company's estimate of
realizable deferred tax assets may change in the near future.
No income tax provisions have been recognized for foreign tax jurisdictions
and no income tax benefits have been recognized for subsidiary losses outside
the domestic consolidated return because they are not expected to reverse in
the foreseeable future.
LIQUIDITY AND CAPITAL RESOURCES
During 1998, the company utilized $7.5 million of cash flow in operations
and $1.4 million in investing activities, while generating $6.4 million from
financing activities, resulting in a $2.5 million decrease in cash. The cash
flow utilized in operations was primarily due to an increase in working
capital, offset by a modest favorable cash impact of the company's 1998 net
loss before non-cash expenses. The increase in working capital consisted
primarily of a $6.6 million increase in inventories, a $2.6 million increase
in trade accounts receivable, and $1.1 million of payments for restructuring
costs. The unfavorable effects on cash from changes in working capital were
partially offset by a $1.5 million increase in customer deposits and $1.0
million of increases in accounts payable and other current liabilities,
resulting in a $7.8 million net unfavorable impact from changes in working
capital. This change was partially offset by the $0.3 million net favorable
impact of $7.1 million of non-cash charges (including depreciation,
amortization, the litigation loss contingency, non-cash inventory adjustments,
and the write-off of deferred income tax assets) included in the $6.8 million
net loss. Cash utilized in investing activities decreased from $1.7 million in
1997 to $1.4 million in 1998, due in part to an increase in
34
<PAGE>
capital expenditures financed through capital lease arrangements. Cash
generated from financing activities during 1998 primarily reflected $6.6
million in borrowings under the company's revolving line of credit agreement,
made to finance operating losses.
During 1997, the company generated $2.4 million of cash flow from
operations, while utilizing $1.7 million in investing and $0.3 million in
financing activities and $0.2 million in other changes in cash, resulting in a
$0.2 million increase in cash. The cash flow from operations was primarily due
to a decrease in working capital, offset by the company's 1997 net loss before
non-cash expenses. The decrease in working capital primarily consisted of a
$3.3 million reduction in inventories and $4.2 million in net collections of
trade accounts receivable. These decreases, along with other working capital
and other changes in net assets of $0.6 million, positively impacted cash flow
from operations. This impact was partially offset by the net loss from
operations before depreciation, amortization, non-cash inventory adjustments,
and the non-cash restructuring charge of $5.6 million and by $0.8 million of
severance and other facility closing costs charged against the restructuring
reserve. (See Note 6 to the Consolidated Financial Statements). Cash utilized
in investing activities decreased from $2.3 million in 1996 to $1.7 million in
1997, due to an increase in capital expenditures financed through capital
lease arrangements and a reduced level, in 1997, of capital investments
related to the development of full field digital mammography. Cash utilized in
financing activities during 1997 reflected $0.5 million in repayments of long-
term debt, offset by the proceeds from sales of common stock of $0.2 million.
During 1996, the company utilized $4.7 million of cash flow in operations
and $2.4 million in investing activities, while generating $9.4 million from
financing activities, resulting in a $2.3 million increase in cash. The
utilization of cash flow in operations was primarily due to an increase in
working capital. The increase in working capital consisted of a $3.3 million
investment in inventories and a $4.3 million reduction in accounts payable.
These working capital increases, which reduced cash flow, were partially
offset by $1.0 million of net collections of trade accounts receivable and by
net earnings before depreciation, amortization, and non-cash inventory
adjustments of $2.5 million. Cash utilized in investing activities of $2.3
million in 1996 was somewhat higher than in other recent years due to a
reduction in capital expenditures financed through capital lease arrangements
and capital investments related to the development of full field digital
mammography. Cash generated from financing activities during 1996 reflected
the company's June 1996 sale of 1,200,000 shares of common stock for $13.1
million, net of related expenses, and the proceeds of other stock sales,
offset by debt reductions, including repayments under the company's line of
credit, totaling $4.3 million.
On December 31, 1998, the company had $0.9 million in cash and cash
equivalents and working capital of $19.1 million. The company has a $15.0
million revolving line of credit arrangement, subject to borrowing base
restrictions. Due to the effects of these restrictions, which are based upon
eligible receivables and inventory, only $11.1 million of the line was
available as of December 31, 1998, of which $4.5 million was unused. The
agreement is secured by the company's accounts receivable, inventories, and
fixed assets and may be called by the lender upon 30 days notice. The
agreement is renewable monthly and such renewals are subject to a fee of
$5,000 per month. The borrowings under the agreement are subject to interest
at one percent over the bank's prime rate of interest, or 9.25% at December
31, 1998. See Note 5 to the Consolidated Financial Statements.
The company has experienced significant losses in four of the five years
ended December 31, 1998 and has also had negative cash flows from operations
in three of those five years, resulting in the depletion of substantially all
of the company's cash. Further, subsequent to the end of 1998, the company
approached its maximum borrowing capacity, in part due to the lease buyout
relating to its Addison, Illinois manufacturing facility (See Note 6 to the
Consolidated Financial Statements), and may be similarly constrained later in
1999. As more fully described in Note 5, the company's principal lender may
withdraw the revolving credit facility at any time upon giving the company
thirty days notice. Any such withdrawal, or any occurrence of the company's
liquidity needs exceeding its available borrowing capacity, would have a
material adverse impact on the company's operations.
The company has taken action to reduce the level of operating losses and the
fixed cash needs of the business, most notably the closure of the Addison
facility. Management believes the benefits of the Addison
35
<PAGE>
closure and consolidation of operations in the Denver facility will be seen in
1999. If the company were to need additional funds for operations, or if the
current lender were to call the credit facility, Management believes it could
obtain financing at or above current levels from multiple lending sources, by
securitizing accounts receivable, inventories, and other tangible assets.
The company has no present plans for capital expenditures in 1999 materially
different from recent years.
RECENT DEVELOPMENTS
On March 29, 1999, the company announced an agreement with General Electric
Company, on behalf of GE Medical Systems, under which 826,666 or 62% of the
1,333,333 shares of Convertible Preferred Stock currently owned by GE Medical
Systems will be exchanged for a non-exclusive right to manufacture the Tilt-C
system. Completion of the necessary technology transfer is required by mid-
April, 1999. The company expects to continue its manufacturing activity for GE
Medical Systems through at least December 1999, the original expiration date
of the OEM contract. See also related discussion at "Item 5-Market for
Registrant's Common Equity and Related Stockholder Matters--Risks Associated
with Shares Eligible for Future Sale" earlier in this report.
The transaction will result in revenue to the company of approximately $6
million, before related expenses. Because the sale is being paid for by CE
Medical Systems in shares of Convertible Preferred Stock, there will be no
cash effect on the company. However, as a result of the attendant reduction in
the number of outstanding shares of Convertible Preferred Stock, the diluted
book value of the company is expected to increase by approximately $.35 per
share, or 10% overall following the transaction.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
Not Applicable.
36
<PAGE>
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information required by this Item is incorporated by reference to the
company's 1999 Proxy Statement to be filed on or prior to April 30, 1999.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this Item is incorporated by reference to the
company's 1999 Proxy Statement to be filed on or prior to April 30, 1999.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information required by this Item is incorporated by reference to the
company's 1999 Proxy Statement to be filed on or prior to April 30, 1999.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information required by this Item is incorporated by reference to the
company's 1999 Proxy Statement to be filed on or prior to April 30, 1999.
37
<PAGE>
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a) Documents filed as part of this report:
1. Financial Statements.
See page F-0 of this Form 10-K.
2. Financial Statement Schedules.
See page F-0 of this Form 10-K.
3. Exhibits.
The following are filed as part of this report:
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION OF EXHIBIT
------- ----------------------
<C> <S>
3.1 Certificate of Incorporation of the Company(1)
3.2 Bylaws of the Company(1)
4.1 Amended and Restated Rights Agreement, dated as of November 3, 1994,
between the company and American Securities Transfer, Inc. which
includes the Certificate of Designation for the Series C Junior
Participating Preferred Stock as Exhibit A and the form of Right
Certificate as Exhibit B(4)
4.2 Certificate of Designation for the Series D Convertible Preferred
Stock(4)
10.1 Agreement, dated October 5, 1990, between the company and Dornier
Medizintechnik GmbH(1)
10.2 Purchase Agreement, dated August 29, 1994, between the company and
General Electric Company on behalf of GE Medical Systems(4)
10.3 Nonemployee Director Stock Option Plan, as amended(5)
10.4 Stock Option Plan(1)
10.5 Retention Bonus Plan(3)
10.6 Lease Agreement, dated July 31, 1992, between the company and JN
Properties(2)
10.7 Stock Purchase Agreement, dated as of June 20, 1995, between the
company and General Electric Company, acting through its GE Medical
Systems Division ("GEMS")(4)
10.8 Registration Rights Agreement, dated as of June 20, 1995, between the
company and GEMS(4)
10.9 Manufacturing and License Agreement, dated as of June 20, 1995,
between the company and GEMS(4)
10.10 Amendment, dated as of June 20, 1995, to Purchase Agreement, dated as
of August 29, 1994, between the company and GEMS(4)
10.11 Agreement dated October 10, 1997, between the company and Ethicon
Endo-Surgery, Inc. with Addendum dated January 28, 1998.(5)
21 List of Subsidiaries(6)
23 Consent of Arthur Andersen LLP(6)
27 Financial Data Schedule(6)
</TABLE>
- --------
(1) Incorporated by reference to the company's Registration Statement on Form
S-1, File No. 33-41537, as filed with the Securities and Exchange
Commission (the "Commission") on July 3, 1991.
38
<PAGE>
(2) Incorporated by reference to the company's Form 10-K for the year ended
December 31, 1992, as filed with the Commission.
(3) Incorporated by reference to the company's Form 10-K for the year ended
December 31, 1994, as filed with the Commission on April 14, 1995.
(4) Incorporated by reference to the company's Form 8-K, as filed with the
Commission on July 3, 1995.
(5) Incorporated by reference to the company's Form 10-K for the year ended
December 31, 1997, as filed with the Commission on March 31, 1998.
(6) Filed herewith.
(b) Reports on Form 8-K
None
(c) Exhibits
See Item 14(a)(3) of this Form 10-K.
(d) Financial Statement Schedules
See F-1 of this Form 10-K.
39
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
FISCHER IMAGING CORPORATION
/s/ Morgan W. Nields
Date: March 29, 1999 By: _________________________________
Morgan W. Nields
Chairman of the Board, Chief
Executive Officer, and Director
Pursuant to the requirements of the Securities Act of 1934, this report has
been signed below by the following persons on behalf of the registrant in the
capacities and on the date indicated.
<TABLE>
<CAPTION>
Signature Title Date
--------- ----- ----
<S> <C> <C>
/s/ Morgan W. Nields Chairman of the Board, Chief March 29, 1999
____________________________________ Executive Officer,
Morgan W. Nields Principal Executive Officer
/s/ William C. Fee Vice President, Finance, March 29, 1999
____________________________________ Principal Accounting and
William C. Fee Financial Officer
/s/ David G. Bragg, M.D. Director March 29, 1999
____________________________________
David G. Bragg, M.D.
/s/ Thomas J. Cable Director March 29, 1999
____________________________________
Thomas J. Cable
/s/ R. John Fletcher Director March 29, 1999
____________________________________
R. John Fletcher
/s/ Kinney L. Johnson Director March 29, 1999
____________________________________
Kinney L. Johnson
/s/ Kathryn A. Paul Director March 29, 1999
____________________________________
Kathryn A. Paul
</TABLE>
40
<PAGE>
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FISCHER IMAGING CORPORATION
CONSOLIDATED FINANCIAL STATEMENTS
INDEX
<TABLE>
<CAPTION>
Page
----
<S> <C>
Report of Independent Public Accountants.................................. F-2
Financial Statements:
Consolidated Balance Sheets--December 31, 1998 and 1997................. F-3
Consolidated Statements of Operations--For the Years Ended December 31,
1998, 1997 and 1996.................................................... F-4
Consolidated Statements of Stockholders' Investment--For the Years Ended
December 31, 1998, 1997 and 1996....................................... F-5
Consolidated Statements of Cash Flows--For the Years Ended December 31,
1998, 1997 and 1996.................................................... F-6
Notes to Consolidated Financial Statements.............................. F-7
</TABLE>
F-1
<PAGE>
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To the Stockholders and Board of Directors of
Fischer Imaging Corporation:
We have audited the accompanying consolidated balance sheets of FISCHER
IMAGING CORPORATION (a Delaware corporation) and subsidiaries as of December
31, 1998 and 1997, and the related consolidated statements of operations,
stockholders' investment and cash flows for each of the three years in the
period ended December 31, 1998. These financial statements are the
responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of Fischer Imaging
Corporation and subsidiaries as of December 31, 1998 and 1997, and the results
of its operations and its cash flows for each of the three years in the period
ended December 31, 1998, in conformity with generally accepted accounting
principles.
/s/ Arthur Andersen LLP
Denver, Colorado,
March 16, 1999.
F-2
<PAGE>
FISCHER IMAGING CORPORATION
CONSOLIDATED BALANCE SHEETS
(AMOUNTS IN THOUSANDS EXCEPT SHARE DATA)
<TABLE>
<CAPTION>
DECEMBER 31,
------------------
1998 1997
-------- --------
<S> <C> <C>
ASSETS
------
CURRENT ASSETS
Cash and cash equivalents................................ $ 929 $ 3,439
Trade accounts receivable, net of allowance for doubtful
accounts of approximately $726 and $778 at December 31,
1998 and 1997, respectively............................. 16,797 14,132
Inventories, net......................................... 22,023 17,373
Deferred income taxes.................................... -- 1,334
Prepaid expenses and other current assets................ 1,098 1,169
-------- --------
Total current assets................................... 40,847 37,447
-------- --------
PROPERTY AND EQUIPMENT (at cost)
Manufacturing equipment.................................. 9,467 9,521
Office equipment and leasehold improvements.............. 5,936 5,563
-------- --------
15,403 15,084
Less--Accumulated depreciation........................... 9,994 9,417
-------- --------
Property and equipment, net............................ 5,409 5,667
-------- --------
INTANGIBLE ASSETS, net (Note 3)............................ 2,957 3,615
DEFERRED INCOME TAXES...................................... -- 668
DEFERRED COSTS AND OTHER ASSETS............................ 1,756 1,747
-------- --------
Total assets........................................... $ 50,969 $ 49,144
======== ========
LIABILITIES AND STOCKHOLDERS' INVESTMENT
----------------------------------------
CURRENT LIABILITIES
Notes payable and current maturities of long-term debt
(Note 5)................................................ $ 6,838 $ 224
Trade accounts payable................................... 5,204 4,876
Accrued salaries and wages............................... 2,225 2,027
Customer deposits........................................ 2,599 1,136
Accrued warranty and installation costs.................. 1,124 1,090
Accrued restructuring costs (Note 6)..................... 1,015 1,180
Deferred service revenue................................. 1,132 771
Other current liabilities................................ 1,615 964
-------- --------
Total current liabilities.............................. 21,752 12,268
LONG-TERM DEBT (Note 5).................................... 587 309
ACCRUED RESTRUCTURING COSTS, LONG-TERM (Note 6)............ -- 900
OTHER NONCURRENT LIABILITIES............................... 200 482
-------- --------
Total liabilities...................................... 22,539 13,959
-------- --------
COMMITMENTS AND CONTINGENCIES (Note 11)
STOCKHOLDERS' INVESTMENT
Common Stock, $.01 par value, 25,000,000 shares
authorized, 6,980,150 and 6,948,648 shares issued and
outstanding at December 31, 1998 and 1997,
respectively............................................ 70 69
Preferred Stock, 5,000,000 shares authorized:
Series C Junior Participating Preferred Stock, $.01 par
value, 500,000 shares authorized, no shares issued and
outstanding............................................ -- --
Series D Convertible Preferred Stock, $.01 par value,
1,333,333 shares authorized, issued and outstanding at
December 31, 1998 and 1997; liquidation preference of
$10,000,000 (Note 7)................................... 13 13
Additional paid-in capital............................... 49,366 49,235
Accumulated deficit...................................... (21,459) (14,656)
Accumulated other comprehensive income................... 440 524
-------- --------
Total stockholders' investment......................... 28,430 35,185
-------- --------
Total liabilities and stockholders' investment......... $ 50,969 $ 49,144
======== ========
</TABLE>
The accompanying notes are an integral part of these balance sheets.
F-3
<PAGE>
FISCHER IMAGING CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands except per share data)
<TABLE>
<CAPTION>
For the Years Ended
December 31,
--------------------------
1998 1997 1996
------- -------- -------
<S> <C> <C> <C>
REVENUES........................................... $59,804 $ 56,908 $77,508
COST OF SALES...................................... 36,883 39,252 47,073
------- -------- -------
Gross profit................................... 22,921 17,656 30,435
------- -------- -------
OPERATING EXPENSES
Research and development......................... 6,394 6,043 6,746
Selling, marketing and service................... 15,299 16,323 18,776
General and administrative....................... 5,284 4,988 4,863
Litigation loss (Note 11)........................ 500 -- --
Restructuring provision (Note 6)................. -- 2,900 --
------- -------- -------
Total operating expenses....................... 27,477 30,254 30,385
------- -------- -------
(LOSS) EARNINGS FROM OPERATIONS.................... (4,556) (12,598) 50
Interest expense................................. (357) (181) (595)
Interest income.................................. 74 271 138
Other income (expense), net...................... 38 (760) (163)
------- -------- -------
LOSS BEFORE INCOME TAXES........................... (4,801) (13,268) (570)
Provision (benefit) for income taxes............. 2,002 -- (209)
------- -------- -------
NET LOSS........................................... $(6,803) $(13,268) $ (361)
======= ======== =======
LOSS PER SHARE (Note 2)
Basic and Diluted ............................... $ (.97) $ (1.91) $ (.06)
======= ======== =======
SHARES USED TO CALCULATE LOSS PER SHARE (Note 2)
Basic and Diluted................................ 6,980 6,949 6,299
======= ======== =======
</TABLE>
The accompanying notes are an integral part of these statements.
F-4
<PAGE>
FISCHER IMAGING CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' INVESTMENT
(AMOUNTS IN THOUSANDS EXCEPT SHARE DATA)
<TABLE>
<CAPTION>
SERIES C
JUNIOR SERIES D ACCUMULATED
COMMON STOCK PARTICIPATING CONVERTIBLE ADDITIONAL OTHER
---------------- PREFERRED PREFERRED PAID-IN ACCUMULATED COMPREHENSIVE COMPREHENSIVE
SHARES AMOUNT STOCK STOCK CAPITAL DEFICIT INCOME (LOSS) LOSS TOTAL
--------- ------ ------------- ----------- ---------- ----------- ------------- ------------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C>
BALANCES, Decem-
ber 31, 1995... 5,550,691 $ 56 $ -- $ 13 $34,679 $ (1,027) $(137) $ 33,584
Shares purchased
under Employee
Stock Purchase
Plan........... 24,522 -- -- -- 114 -- -- 114
Exercise of
stock options.. 81,960 1 -- -- 475 -- -- 476
Tax benefit from
exercise of op-
tions.......... -- -- -- -- 163 -- -- 163
Acquisition of
minority inter-
est............ 63,162 -- -- -- 553 -- -- 553
Sale of
1,200,000
shares of Com-
mon Stock, net
of related
costs.......... 1,200,000 12 -- -- 13,109 -- -- 13,121
Cumulative
translation ad-
justment....... -- -- -- -- -- -- 155 $ 155 155
Net loss........ -- -- -- -- -- (361) -- (361) (361)
--------
Comprehensive
loss........... -- -- -- -- -- -- -- $ (206) --
--------- ---- ----- ---- ------- -------- ----- ======== --------
BALANCES, Decem-
ber 31, 1996... 6,920,335 69 -- 13 49,093 (1,388) 18 47,805
Shares purchased
under Employee
Stock Purchase
Plan........... 21,463 -- -- -- 112 -- -- 112
Exercise of
stock options.. 6,850 -- -- -- 30 -- -- 30
Cumulative
translation ad-
justment....... -- -- -- -- -- -- 506 $ 506 506
Net loss........ -- -- -- -- -- (13,268) -- (13,268) (13,268)
--------
Comprehensive
loss........... -- -- -- -- -- -- -- $(12,762) --
--------- ---- ----- ---- ------- -------- ----- ======== --------
BALANCES, Decem-
ber 31, 1997... 6,948,648 69 -- 13 49,235 (14,656) 524 35,185
Shares purchased
under Employee
Stock Purchase
Plan........... 31,502 1 -- -- 131 -- -- 132
Cumulative
translation ad-
justment....... -- -- -- -- -- -- (84) $ (84) (84)
Net loss........ -- -- -- -- -- (6,803) -- (6,803) (6,803)
--------
Comprehensive
loss........... -- -- -- -- -- -- -- $ (6,887) --
--------- ---- ----- ---- ------- -------- ----- ======== --------
BALANCES, Decem-
ber 31, 1998... 6,980,150 $ 70 $ -- $ 13 $49,366 $(21,459) $ 440 $ 28,430
========= ==== ===== ==== ======= ======== ===== ========
</TABLE>
The accompanying notes are an integral part of these statements.
F-5
<PAGE>
FISCHER IMAGING CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
<TABLE>
<CAPTION>
For the Years Ended
December 31,
--------------------------
1998 1997 1996
------- -------- -------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss........................................ $(6,803) $(13,268) $ (361)
------- -------- -------
Adjustments to reconcile net loss to net cash
(used in)
provided by operating activities--
Restructuring provision........................ -- 2,900 --
Depreciation................................... 2,271 1,981 1,629
Amortization of intangible assets.............. 658 712 741
Litigation loss contingency.................... 500 -- --
Provision for doubtful accounts................ 41 256 358
Provision for excess and obsolete inventories.. 1,638 2,028 532
Deferred income tax provision (benefit)........ 2,002 611 (369)
Sales and retirements of assets................ 244 170 62
Restructuring costs............................ (1,065) (820) --
Foreign exchange (gains) losses................ (131) 720 130
Other changes in current assets and
liabilities--
(Increase) decrease in trade accounts
receivable.................................. (2,706) 4,212 999
(Increase) decrease in inventories........... (6,611) 3,331 (3,263)
Decrease (increase) in prepaid expenses and
other current assets........................ 71 120 (168)
Increase (decrease) in trade accounts
payable..................................... 328 (279) (4,285)
Increase (decrease) in accrued salaries and
wages....................................... 198 (133) (32)
Increase (decrease) in customer deposits..... 1,463 78 (27)
Increase (decrease) in accrued warranty and
installation costs.......................... 34 (318) 268
Increase (decrease) in deferred service
revenue..................................... 361 (34) (242)
Increase (decrease) in other current
liabilities................................. 151 (157) (580)
Other.......................................... (191) 299 (129)
------- -------- -------
Total adjustments............................ (744) 15,677 (4,376)
------- -------- -------
Net cash (used in) provided by operating
activities.................................. (7,547) 2,409 (4,737)
------- -------- -------
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures............................ (1,299) (1,728) (2,300)
Other........................................... (100) -- (48)
------- -------- -------
Net cash used in investing activities........ (1,399) (1,728) (2,348)
------- -------- -------
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock, net......... 132 142 13,711
Net borrowings (repayments) under line of credit
agreement...................................... 6,572 -- (2,643)
Repayments of long-term debt.................... (315) (459) (1,687)
------- -------- -------
Net cash provided by (used in) financing
activities.................................. 6,389 (317) 9,381
------- -------- -------
EFFECT OF EXCHANGE RATE CHANGES ON CASH........... 47 (214) 25
------- -------- -------
NET (DECREASE) INCREASE IN CASH AND CASH
EQUIVALENTS...................................... (2,510) 150 2,321
CASH AND CASH EQUIVALENTS, beginning of period.... 3,439 3,289 968
------- -------- -------
CASH AND CASH EQUIVALENTS, end of period.......... $ 929 $ 3,439 $ 3,289
======= ======== =======
SUPPLEMENTAL CASH FLOW DISCLOSURES
Cash interest payments.......................... $ 397 $ 119 $ 599
Cash income tax (refunds) payments, net......... (416) (308) 1,016
Non-cash capital expenditures (capital lease
financing)..................................... 635 560 40
Non-cash acquisition of minority interest....... -- -- 553
Non-cash tax benefit from exercise of stock
options........................................ -- -- 163
</TABLE>
The accompanying notes are an integral part of these statements.
F-6
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For the Three Years Ended December 31, 1998, 1997 and 1996
(1) BUSINESS ORGANIZATION
Fischer Imaging Corporation (the "Company"), a Delaware Corporation, and its
foreign marketing subsidiaries, 100%-owned Fischer Imaging Australia Pty.
Limited ("FIA") and 90% owned Fischer Imaging Europe A/S ("FIE") designs,
manufactures, and markets specialty and general purpose x-ray imaging systems
for the diagnosis and treatment of disease. The Company's principal product
lines are directed toward medical specialties in which minimally invasive
techniques are replacing open surgical procedures. The Company's existing
products are principally marketed to the healthcare industry.
Liquidity and Continuing Losses
The Company has experienced significant losses in four of the last five
years ended December 31, 1998 and has also had negative cash flows from
operations in three of those five years, resulting in the depletion of
substantially all of the Company's cash. Further, subsequent to the end of
1998, the Company approached its maximum borrowing capacity, in part due to
the lease buyout relating to its Addison, Illinois manufacturing facility (See
Note 6), and may be similarly constrained later in 1999. At December 31, 1998,
the Company had approximately $6.6 million of outstanding borrowings under its
revolving line of credit agreement, while the borrowing base was approximately
$11.1 million. As more fully described in Note 5, the Company's principal
lender may withdraw the revolving credit facility at any time upon giving the
Company thirty days notice. If this were to occur, or if the Company's needs
were to exceed its current borrowing capacity, it could have an adverse impact
on the Company's operations.
The Company has taken actions to reduce the level of operating losses and
the fixed cash needs of the business, most notably the closure of the Addison
facility. Management believes the benefits of the Addison closure and
consolidation of operations in the Denver facility will be seen in 1999. If
the Company were to need additional funds for operations, or if the current
lender were to call the credit facility, management believes it can obtain
financing at or above current levels from multiple sources by securitizing
accounts receivable, inventories, and other tangible assets.
(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
The consolidated financial statements include those of the Company and all
of its majority-owned subsidiaries. Investments in less than 20%-owned
companies are accounted for at the lower of cost or estimated long-term
realizable value. All significant intercompany transactions have been
eliminated in consolidation.
Use of Estimates in the Preparation of Financial Statements
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions. Such estimates and assumptions affect the reported amounts of
assets and liabilities as well as disclosure of contingent assets and
liabilities at the date of the financial statements, and the reported amounts
of revenue and expenses during the reporting period. Actual results could
differ from those estimates.
Cash and Cash Equivalents
Cash and cash equivalents include investments in highly liquid instruments
with an original maturity of three months or less.
F-7
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Financial Instruments
The fair market value of accounts receivable, accounts payable, debt, and
other financial instruments approximates their carrying values in the
accompanying balance sheets. The Company does not enter into derivative
contracts to manage its interest rate or foreign exchange risk.
Inventories
Inventories, which include costs of materials, direct labor, and
manufacturing overhead, are priced at the lower of cost (using primarily the
last-in, first-out ("LIFO") method of valuation) or market. Writedowns for
excess and obsolete inventories are charged to expense in the period when
conditions giving rise to the writedowns are first recognized.
Inventories consist of the following components (in thousands):
<TABLE>
<CAPTION>
1998 1997
------- -------
<S> <C> <C>
FIFO cost--
Raw materials............................................ $14,684 $11,960
Work in process and finished goods....................... 14,099 11,705
LIFO valuation adjustment.................................. (520) (586)
------- -------
Total before valuation reserves.......................... 28,263 23,079
Less valuation reserves.................................... (6,240) (5,706)
------- -------
Inventories, net......................................... $22,023 $17,373
======= =======
</TABLE>
Property and Equipment
Significant additions and improvements are capitalized at cost, while
maintenance and repairs which do not improve or extend the life of the
respective assets are charged to operations as incurred.
Manufacturing and office equipment are depreciated on a straight-line basis,
over the estimated useful lives (ranging from 3 to 8 years) of the respective
assets. Leasehold improvements are amortized, on a straight-line basis, over
the lesser of the estimated useful life or the remaining term of the related
lease.
Service Parts
Service parts used for servicing installed equipment that are not currently
active production parts are stated at cost and depreciated on a straight-line
basis over five years. The Company capitalizes service parts as a component of
manufacturing equipment in the accompanying consolidated balance sheets.
Long-Lived Assets
Long-Lived assets are reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable. In performing the review for recoverability, the Company
estimates the future cash flows expected to result from the use of the asset
and its eventual disposition. If the sum of the expected future cash flows
(undiscounted and without interest charges) is less than the carrying amount
of the asset, an impairment loss is recognized. Otherwise, an impairment loss
is not recognized.
Intangible Assets
Intangible assets resulting from acquisitions are stated at cost, net of
accumulated amortization, and are being amortized using the straight-line
method over their estimated useful lives which range from 10 to 15 years.
Other intangible assets, comprised primarily of licensing agreements, are
amortized over periods ranging from 3 to 7 years.
F-8
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Software Development Costs
Certain costs to enhance existing application software products or to
develop new software products have been capitalized. These costs are amortized
on a straight-line basis over an estimated useful life of three years.
As of December 31, the following amounts were reflected in the consolidated
balance sheets as a component of deferred costs and other assets (in
thousands):
<TABLE>
<CAPTION>
1998 1997
------- -------
<S> <C> <C>
Cost....................................................... $ 3,539 $ 3,196
Less--Accumulated amortization............................. (2,999) (2,639)
------- -------
Software development costs, net.......................... $ 540 $ 557
======= =======
</TABLE>
Other Current Liabilities
Other current liabilities consist of the following (in thousands):
<TABLE>
<CAPTION>
1998 1997
------ ----
<S> <C> <C>
Accrued sales, property, and other state and local taxes......... $ 594 $688
Litigation loss contingency reserve.............................. 500 --
Other............................................................ 521 276
------ ----
Total other current liabilities................................ $1,615 $964
====== ====
</TABLE>
Foreign Operations
The functional currency for the Company's foreign operations is the
applicable local currency. Assets and liabilities of foreign subsidiaries are
translated at the respective year end exchange rates, while the statements of
operations are translated at average exchange rates during the year. Exchange
rate fluctuations on translating foreign currency into U.S. dollars result in
unrealized gains or losses referred to as translation adjustments, which are
recorded as a separate component of stockholders' investment. Transactions
denominated in other than a foreign operation's functional currency can also
result in exchange gains or losses being reflected in the results of
operations. Foreign currency gains or losses are included in the consolidated
statements of operations as a component of other income (expense).
Revenue Recognition
The Company recognizes revenue when title and risk of ownership passes to
the customer which generally, as to shipments with FOB destination terms, is
when received by the customer and, for shipments with FOB shipping point
terms, is upon departure from the Company's dock. The related costs of
warranty and installation obligations are recognized at the time of sale.
Advertising Costs
The Company expenses advertising costs as incurred, except for the costs of
advertising literature, which are capitalized and amortized over the expected
period of future benefit.
Sponsored Research and Development
The Company from time to time engages in research and development activities
for other companies. This sponsored research and development is recognized as
revenue as the requirements are fulfilled or as certain
F-9
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
development milestones are completed under the terms and conditions of the
related research and development agreements. Costs incurred in connection with
these activities are recognized in cost of sales as incurred.
Net Earnings or Loss Per Share
The Company presents basic and diluted earnings or loss per share in
accordance with Statement of Financial Accounting Standards No. 128 "Earnings
per Share" ("SFAS 128"), which establishes standards for computing and
presenting basic and diluted earnings per share. Under this statement, basic
earnings or loss per share is computed by dividing the net earnings or loss by
the weighted average number of shares of common stock outstanding. Diluted
earnings or loss per share is determined by dividing the net earnings or loss
by the sum of (1) the weighted average number of common shares outstanding,
(2) if not anti-dilutive, the number of shares of convertible preferred stock
(Note 7) as if converted upon issuance, and (3) if not anti-dilutive, the
effect of outstanding stock options determined utilizing the treasury stock
method.
A reconciliation between the number of securities used to calculate basic
and, where anti-dilutive, diluted earnings per share is as follows:
<TABLE>
<CAPTION>
1998 1997 1996
----- ----- -----
<S> <C> <C> <C>
Weighted average number of common shares outstanding
(Shares used in Basic Earnings Per Share Computation).... 6,980 6,949 6,299
----- ----- -----
Shares of convertible preferred stock (as if converted)... 1,333 1,333 1,333
Effect of stock options (treasury stock method)........... 1 23 344
----- ----- -----
Shares used in Diluted Earnings Per Share Computation, if
dilutive................................................. 8,314 8,305 7,976
===== ===== =====
</TABLE>
In 1998, 1997, and 1996, the effects of the convertible preferred stock and
stock options were excluded from the calculation of diluted loss per share
since the result would have been anti-dilutive. As of December 31, 1998 and
1997, there were, respectively, 857,925 and 865,000 outstanding options to
purchase shares of Common Stock, under the 1993 Nonemployee Director Stock
Option Plan and the 1991 Stock Option Plan.
Recently Issued Accounting Pronouncements
Statement of Position 98-1. In March 1998, the American Institute of
Certified Public Accountants ("AICPA") issued Statement of Position 98-1 ("SOP
98-1"), "Accounting for the Costs of Computer Software Developed or Obtained
for Internal Use". In general, SOP 98-1 requires that certain costs to develop
software for internal use be capitalized. This statement is effective for
fiscal years beginning after December 15, 1998, although earlier adoption is
permitted. These requirements are to be applied prospectively from the date of
adoption. The Company believes SOP 98-1 will not materially impact its
financial statements.
Statement of Position 98-5. In April 1998, the AICPA issued Statement of
Position 98-5 ("SOP 98-5"), "Reporting on the Costs of Start-Up Activities".
SOP 98-5 provides guidance on the financial reporting of start-up and
organization costs and requires costs of start-up activities and organization
costs to be expensed as incurred. SOP 98-5 is effective for fiscal years
beginning after December 15, 1998. The Company believes SOP 98-5 will not
materially impact its financial statements.
Statement of Financial Accounting Standards No. 133. In June 1998, the
Financial Accounting Standards Board issued Statement of Financial Accounting
Standards No. 133, "Accounting for Derivative Instruments and Hedging
Activities" ("Statement No. 133"). Statement No. 133 establishes accounting
and reporting standards requiring that every derivative instrument (including
certain derivative instruments embedded in other contracts) be recorded in the
balance sheet as either an asset or liability measured at its fair market
value. The statement
F-10
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
requires that changes in the derivative's fair value be recognized currently
in earnings unless specific hedge accounting criteria are met. Special
accounting for qualifying hedges allows a derivative's gains and losses to
offset related results on the hedged item in the income statement, and
requires that a company formally document, designate, and assess the
effectiveness of transactions that receive hedge accounting.
Statement No. 133 is effective for fiscal years beginning after June 15,
1999. A company may also implement the Statement as of the beginning of any
fiscal quarter after issuance (that is, fiscal quarters beginning June 16,
1998 and thereafter). Statement No. 133, which cannot be applied
retroactively, must be applied to (a) derivative instruments and (b) certain
derivative instruments embedded in hybrid contracts that were issued,
acquired, or substantively modified after December 31, 1997 (and, at the
Company's election, before January 1, 1998).
The Company does not typically enter into arrangements that would fall under
the scope of Statement No. 133. The Company's management has not yet
quantified the impacts of adopting Statement No. 133 on the Company's
financial statements and has not determined the timing of or method of the
Company's adoption of Statement No. 133. However, should the Company determine
to utilize the arrangements covered by Statement No. 133, Statement No. 133
could increase volatility in earnings and other comprehensive income. Because
the Company has not historically entered into such arrangements, management
believes that Statement No. 133 will not significantly affect its financial
reporting.
Stock-Based Compensation Plans
The Company accounts for its stock-based compensation plans under the
intrinsic value method prescribed by Accounting Principles Board Opinion No.
25, "Accounting for Stock Issued to Employees" ("APB No. 25"). The Company has
adopted the disclosure option of Statement of Financial Accounting Standards
No. 123, "Accounting for Stock-Based Compensation" ("SFAS 123"). SFAS 123
requires companies that do not account for stock-based compensation under the
fair value method prescribed by the statement to disclose the pro forma
earnings and earnings per share as if the fair value method had been adopted.
Additionally, certain other disclosures are required with respect to stock
compensation and the assumptions used to determine the pro forma effects of
SFAS 123.
Reclassifications
Certain reclassifications have been made in the financial statements of
prior years to conform to the current year presentation.
(3) INTANGIBLE ASSETS
Intangible assets consist of the following (in thousands):
<TABLE>
<CAPTION>
1998 1997
------- -------
<S> <C> <C>
Goodwill................................................... $ 2,785 $ 2,785
Non-competition agreement.................................. 3,569 3,569
Licensing agreements and other............................. -- 828
------- -------
6,354 7,182
Less--Accumulated amortization............................. (3,397) (3,567)
------- -------
Intangible assets, net................................... $ 2,957 $ 3,615
======= =======
</TABLE>
The non-competition agreement and substantially all of the goodwill resulted
from the Company's September 1992 acquisition of Bloom Associates, Ltd.
F-11
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
(4) INCOME TAXES
The provision for income taxes includes the following (in thousands):
<TABLE>
<CAPTION>
1998 1997 1996
------- ------- -----
<S> <C> <C> <C>
Current
Federal.......................................... $ -- $ (471) $ 299
State............................................ -- (140) 104
------- ------- -----
Total current (benefit) provision.............. -- (611) 403
------- ------- -----
Deferred
Federal.......................................... (1,211) (3,458) (102)
State............................................ (142) (296) (10)
Valuation allowance.............................. 3,355 4,365 (500)
------- ------- -----
Total deferred provision (benefit)............. 2,002 611 (612)
------- ------- -----
Total provision (benefit).................... $ 2,002 $ -- $(209)
======= ======= =====
</TABLE>
The statutory federal income tax rate was 35% for the years ended December
31, 1998, 1997, and 1996. Reasons for the difference between the income tax
expense reported in the statements of operations and the amount computed by
applying the statutory federal income tax rate to earnings before income taxes
are as follows:
<TABLE>
<CAPTION>
1998 1997 1996
----- ----- -----
<S> <C> <C> <C>
Statutory tax rate........ (35.0)% (35.0)% (35.0)%
Increase (decrease) due
to:
State income taxes...... (3.3) (4.7) (2.1)
Loss of subsidiaries not
in tax return.......... 9.1 4.1 72.4
Nondeductible expenses.. 1.0 1.0 24.0
Foreign sales
corporation
commissions............ -- -- (11.6)
Valuation allowance on
net deferred tax
assets................. 69.9 32.9 (87.7)
Other................... -- 1.7 3.3
----- ----- -----
Effective tax rate........ 41.7 % -- % (36.7)%
===== ===== =====
</TABLE>
A tax benefit of $163,000, resulting from the sale of option shares by
employees, has been allocated to additional paid-in capital during 1996.
The domestic versus foreign component of the Company's (loss) earnings
before income taxes is as follows (in thousands):
<TABLE>
<CAPTION>
1998 1997 1996
------- -------- -------
<S> <C> <C> <C>
Domestic......................................... $(4,363) $(11,684) $ 644
Foreign.......................................... (438) (1,584) (1,214)
------- -------- -------
Total.......................................... $(4,801) $(13,268) $ (570)
======= ======== =======
</TABLE>
No income tax provisions have been recognized for foreign tax jurisdictions
and no income tax benefits have been recognized for subsidiary losses outside
the domestic consolidated return because they are not expected to reverse in
the foreseeable future.
F-12
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Components of net deferred tax assets (liabilities) as of December 31, 1998
and 1997 are as follows (in thousands):
<TABLE>
<CAPTION>
1998 1997
------- -------
<S> <C> <C>
Current--
Warranty reserves....................................... $ 308 $ 319
Inventory reserves...................................... 2,435 2,145
Bad debt reserves....................................... 276 296
Accrued vacation........................................ 191 216
Restructuring reserve................................... 386 448
Litigation loss reserve................................. 190 --
Other accrued liabilities............................... 48 132
Other................................................... 122 107
Less--Valuation allowance............................... (3,956) (2,329)
------- -------
Net current deferred tax asset............................ $ -- $ 1,334
======= =======
Noncurrent--
Software capitalization................................. $ (205) $ (212)
Tax credits............................................. 908 877
Deferred service revenue................................ 133 177
Restructuring reserve................................... -- 342
Net operating loss carryforward......................... 3,919 2,495
Other................................................... 61 77
Less--Valuation allowance............................... (4,816) (3,088)
------- -------
Net noncurrent deferred tax asset......................... $ -- $ 668
======= =======
</TABLE>
For income tax reporting purposes, the Company has approximately $10,314,000
of net operating loss carryforwards that expire at various dates through 2012.
The Company also has available income tax credits of approximately $742,000,
expiring at various dates through 2009, and alternative minimum tax credits of
$166,000. Realization is dependent on generating sufficient taxable income
prior to the expiration dates of the respective tax credits.
During 1998 and 1997, the Company increased its valuation allowance by
$3,355,000 and $4,365,000, respectively, due mainly to uncertainty relating to
the realizability of the 1998 and 1997 net operating loss carryforwards and
the previously described available income tax credits. The amount of the
deferred tax asset considered realizable could be adjusted in the near term if
future taxable income materializes.
(5) NOTES PAYABLE AND LONG-TERM DEBT
Notes payable and long-term debt as of December 31, 1998 and 1997, consist
of the following (in thousands):
<TABLE>
<CAPTION>
1998 1997
------- -----
<S> <C> <C>
Note payable under revolving line of credit................. $ 6,572 $ --
Capitalized lease obligations; interest rates ranging from
6% to 19%; monthly principal and interest payments due in
varying amounts through August 2002; secured by leased
equipment.................................................. 827 505
Other....................................................... 26 28
------- -----
7,425 533
Less--Current maturities.................................... (6,838) (224)
------- -----
Long-term debt.............................................. $ 587 $ 309
======= =====
</TABLE>
F-13
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Revolving Credit Agreement
The Company has available up to $15.0 million of credit, subject to further
restrictions based on eligible receivables, inventory, and Company liquidation
value. The maximum amount which could have been drawn under these borrowing
base restrictions was approximately $11.1 million as of December 31, 1998. The
revolving credit agreement is renewable on a monthly basis and is secured by
the Company's accounts receivable, inventory, and fixed assets. Renewals are
subject to a renewal fee of $5,000 per month, and borrowings under the
agreement bear interest at one percent over the bank's prime rate of interest,
or 9.25% at December 31, 1998.
Future maturities of notes payable and long-term debt are as follows (in
thousands):
<TABLE>
<S> <C>
Year ended December 31,
1999............................................................ $6,838
2000............................................................ 235
2001............................................................ 173
2002............................................................ 179
------
Total........................................................... $7,425
======
</TABLE>
(6) RESTRUCTURING PROVISION
During 1997, the Company decided to close its Addison, Illinois
manufacturing facility and, accordingly, recorded a $2.9 million restructuring
provision for remaining lease obligations (through June 2002), net of
estimated sublease payments, estimated facility closing costs, severance and
certain other non-recurring costs associated with this decision. During the
years ended December 31, 1998 and 1997, the Company spent approximately $1.1
million and $0.8 million, respectively, for severance and facility closing
costs. In January 1999, the Company fulfilled its remaining obligations for
this facility by agreeing to a $1.0 million lease buyout, completing the
Addison closure within the original $2.9 million provision.
(7) STOCKHOLDERS' INVESTMENT
The Company is authorized to issue 5,000,000 shares of $.01 par value
preferred stock, which may be issued in one or more series and with such
powers, preferences and rights as the Company's Board of Directors may
determine. In June 1995, the Company issued 1,333,333 shares of Series D
Convertible Preferred Stock to GE Medical Systems ("GEMS") for $10 million.
The preferred stock is non-voting and not redeemable, bears no stated
dividend, has a $7.50 per share preference upon liquidation and is convertible
into common stock on a one-for-one basis (subject to customary anti-dilution
protection) at the option of the holder. The terms of the investment restrict
GEMS to 25% ownership of the Company and, under certain change of control
conditions, permit GEMS to exchange its preferred stock for rights to
independently manufacture Tilt-C systems.
On June 27, 1996, the Company completed the sale of 1,200,000 shares of its
common stock at $12.00 per share. Proceeds, net of underwriting discount and
other expenses, of $13.1 million were primarily utilized to repay
approximately $6.4 million of existing indebtedness under the Company's bank
revolving credit agreement. The remaining proceeds were invested in short-
term, investment grade securities. If the sale of common shares had been
completed as of the beginning of the year, and assuming the proceeds and
utilization of proceeds remained the same, earnings per share for the year
ended December 31, 1996 would have been increased by $.02.
F-14
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
(8) EMPLOYEE BENEFIT PLANS
1991 Stock Option Plan
The Company's 1991 Stock Option Plan ("1991 Plan"), adopted June 1991 and as
subsequently amended, authorizes the granting of incentive and nonqualified
stock options to acquire up to 1,250,000 shares of the Company's common stock
by employees and consultants of the Company. Exercise terms for the options
granted are determined by the Board of Directors at the time of grant.
Incentive stock options may be granted at an exercise price not less than fair
market value on the date of grant with a maximum option term of 10 years. The
1991 Plan also permits the granting of stock appreciation rights, although
none have been granted.
A summary of the status of the 1991 Plan as of December 31, 1998, 1997, and
1996 and the changes during those periods is as follows:
<TABLE>
<CAPTION>
1998 1997 1996
------------ ------------ ------------
<S> <C> <C> <C>
Outstanding at January 1......... 764,000 709,625 895,625
Granted.......................... 162,500 185,000 513,000
Exercised........................ -- (6,850) (75,550)
Canceled......................... (157,575) (123,775) (623,450)
------------ ------------ ------------
Outstanding at December 31....... 768,925 764,000 709,625
============ ============ ============
Exercisable at December 31....... 321,968 247,844 134,250
============ ============ ============
Range of exercise prices, at end
of period....................... $3.06-$11.00 $4.00-$11.00 $4.00-$11.00
Weighted average exercise prices:
At beginning of period......... $ 5.91 $ 5.91 $ 8.34
At end of period............... 5.56 5.91 5.91
Exercisable at end of period... 6.03 6.23 7.01
Options granted................ 4.15 5.85 5.81
Options exercised.............. -- 4.38 6.40
Options canceled............... 5.82 5.91 9.31
Weighted average end of period
remaining contractual life (in
years).......................... 7.4 8.2 8.6
Weighted average fair value of
options granted during period... $ 2.36 $ 3.89 $ 2.91
</TABLE>
F-15
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
The following summary shows, as of December 31, 1998 and for the price
ranges indicated, the weighted average exercise price, weighted average
exercise price of options exercisable, and the remaining contractual life of
options granted under the 1991 Plan:
<TABLE>
<CAPTION>
Range of exercise prices Shares Price
------------------------ ------- ------
<S> <C> <C>
Weighted average exercise price for options
outstanding:
$3.06-$4.99.......................................... 182,500 $ 4.05
$5.00-$5.99.......................................... 513,000 5.70
$6.00-$7.99.......................................... 42,500 6.91
$8.00-$11.00......................................... 30,925 10.30
Weighted average exercise price for options
exercisable:
$3.06-$4.99.......................................... 44,167 $ 4.45
$5.00-$5.99.......................................... 224,709 5.64
$6.00-$7.99.......................................... 22,167 7.11
$8.00-$11.00......................................... 30,925 10.30
Weighted average remaining contractual life (in years):
$3.06-$4.99.......................................... 182,500 $ 8.59
$5.00-$5.99.......................................... 513,000 7.20
$6.00-$7.99.......................................... 42,500 6.64
$8.00-$11.00......................................... 30,925 3.70
</TABLE>
The weighted average fair value of each option grant has been estimated as
of the date of grant using the Black-Scholes option-pricing model and the
following assumptions:
<TABLE>
<CAPTION>
1998 1997 1996
----- ----- -----
<S> <C> <C> <C>
Dividend rate....................................... 0% 0% 0%
Expected volatility................................. 78% 77% 78%
Risk-free interest rate............................. 5.55% 5.92% 5.67%
Expected life (in years)............................ 4.5 5.0 3.0
</TABLE>
Certain of the options granted under the 1991 Plan vest upon attainment of
performance objectives as well as over time. As of December 31, 1998, 95,000
options granted in December 1996 with an exercise price of $5.81 per share,
vest upon the earlier of (1) when the market value of the Company's stock has
reached targeted price levels for a period of 20 consecutive trading days, (2)
upon the attainment of certain annual earnings per share targets, or (3) 25%
six months from date of grant, with the remainder vesting in equal monthly
installments over the following 24 months. Also outstanding as of December 31,
1998 are 160,000 options granted in December 1995 that vest when the market
value of the Company's stock has reached targeted price levels for a period of
45 consecutive trading days or 9 years and 11 months from the date of original
grant, whichever is earlier. Other options granted under the 1991 Plan vest
ratably over time, generally over a four year period.
Nonemployee Director Stock Option Plan
The Company's Nonemployee Director Stock Option Plan ("Director Plan"),
adopted in 1993 and as amended in June 1998, authorizes the granting of
nonqualified options to acquire up to 300,000 shares of common stock at a
price not less than fair market value on the date of grant. The Director Plan
allows for automatic annual grants upon each year of a director's service. The
stock options issued under the Director Plan may be exercised at any time from
date of grant, with a maximum option term of ten years.
At the Company's June 1998 Annual Meeting, to acknowledge the services
provided by its nonemployee directors and to increase the Company's ability to
retain such Directors, stockholders approved certain
F-16
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
amendments to the Director Plan and the repricing of certain previously
granted outstanding options, in view of the significant decline in the market
value of the Company's common stock. The repricing resulted in the exercise
price of 68,000 options being reduced to $4.25 from a range of $4.69 to
$13.38. The repricing did not have a material impact on the Company's
operating results.
A summary of the status of the Director Plan as of December 31, 1998, 1997,
and 1996 and the changes during those periods is as follows:
<TABLE>
<CAPTION>
1998 1997 1996
----------- ------------ ------------
<S> <C> <C> <C>
Outstanding at January 1............ 101,000 64,000 46,000
Granted............................. 24,000 37,000 18,000
Cancelled........................... (36,000) -- --
----------- ------------ ------------
Outstanding and Exercisable at
December 31........................ 89,000 101,000 64,000
=========== ============ ============
Range of exercise prices, at end of
period............................. $4.00-$4.25 $4.00-$13.38 $4.00-$13.38
Weighted average exercise prices:
Outstanding, at beginning of
period........................... $ 7.76 $ 8.36 $ 6.40
Outstanding, at end of period..... 4.20 7.76 8.36
Exercisable, at end of period..... 4.20 7.76 8.36
Options granted................... 4.19 6.72 13.38
Options cancelled................. 7.96 -- --
Weighted average remaining end of
period contractual life (in
years)............................. 2.7 2.6 2.7
Weighted average fair value of
options granted during period...... $ 2.29 $ 3.65 $ 5.98
</TABLE>
The following summary shows, as of December 31, 1998 and for the price
ranges indicated, the weighted average exercise price for outstanding options,
all of which are exercisable, and the remaining contractual life of options
granted under the Director Plan:
<TABLE>
<CAPTION>
Life
Range of exercise prices Shares Price (in years)
------------------------ ------ ----- ----------
<S> <C> <C> <C>
Weighted average exercise price for options
outstanding (all of which are exercisable):
$4.00-$4.25..................................... 89,000 $4.20 2.66
</TABLE>
The weighted average fair value of each option grant has been estimated as
of the date of grant using the Black-Scholes option-pricing model and the
following assumptions:
<TABLE>
<CAPTION>
1998 1997 1996
----- ----- -----
<S> <C> <C> <C>
Dividend rate........................................... 0% 0% 0%
Expected volatility..................................... 78% 77% 78%
Risk-free interest rate................................. 5.41% 6.39% 5.67%
Expected life (in years)................................ 3.0 3.0 2.0
</TABLE>
Employee Stock Purchase Plan
Under the Employee Stock Purchase Plan ("Employee Plan"), adopted in
December 1991 and as amended in June 1998, the Company is authorized to issue
up to 400,000 shares of common stock to its full-time employees, nearly all of
whom are eligible to participate. Under terms of the Employee Plan, employees
can have from 2% to 5% of their salary withheld to purchase the Company's
common stock. The purchase price of
F-17
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
the stock is 85% of the lower of its beginning-of-the-year or end-of-year
market price. Under the Employee Plan, the Company issued 31,502, 21,463 and
24,522 shares during the years ended December 31, 1998, 1997, and 1996,
respectively, relating to employee withholdings from the preceding years.
Stock-Based Compensation Plans
The fair value of the stock options granted in 1998, 1997, and 1996 was
estimated to be approximately $0.5 million, $0.9 million, and $1.2 million,
respectively, which, under SFAS 123, would be amortized as compensation
expense over the vesting period of the options. Had compensation cost been
recorded consistent with SFAS 123 utilizing the assumptions detailed above,
the Company's pro forma net loss and net loss per share would have been as
follows for the years ended December 31 (in thousands, except per share data):
<TABLE>
<CAPTION>
1998 1997 1996
------- -------- ------
<S> <C> <C> <C>
Net loss:
As reported.................................... $(6,803) $(13,268) $ (361)
Pro forma...................................... (7,364) (13,589) (541)
Net loss per common share, diluted:
As reported.................................... $ (.97) $ (1.91) $(0.06)
Pro forma...................................... (1.06) (1.96) (0.09)
</TABLE>
401(k) Plan
In 1985, the Company established The Fischer Imaging Employee Capital
Accumulation Plan, which is governed by Section 401(k) of the Internal Revenue
Code. Employees with a minimum of six months of service are eligible for the
plan. The Company makes discretionary contributions which vest over a four-
year period. There were no Company contributions for the years ended December
31, 1998, 1997, and 1996.
Incentive Compensation Plan
The Company has an incentive compensation plan under which management
employees, including the Company's executive officers, receive cash bonuses.
The amounts of such bonuses are determined based upon the Company's sales
growth, profitability, and employees' performances as compared to performance
objectives established by the Board of Directors. During the years ended 1998,
1997, and 1996, the Company accrued bonuses of approximately $0.1 million,
$0.1 million, and $0, respectively, under this plan.
(9) RELATED PARTY TRANSACTIONS
The Company leases its manufacturing and administrative facility from JN
Properties (a general partnership whose partners include the Company's
chairman/chief executive officer and another stockholder/director of the
Company). The lease, which expires in July 2012, provides for adjustments of
base rent in 2000, 2005, and 2010, based on the then fair market rental value
of the premises. The increases are subject to a 7% maximum increase in each
adjustment year. The current annual rent is $744,000. All taxes, insurance,
and maintenance expenses of the facility are the responsibility of the
Company.
In the second quarter of 1995, the Company issued 1,333,333 shares of Series
D Convertible Preferred Stock to GEMS (see Note 7), currently representing a
16% ownership interest in the Company on an if-converted basis. GEMS is also a
significant customer, providing revenues to the Company of approximately $3.5
million or 5.9% and $4.3 million or 7.5% of total revenues, in 1998 and 1997,
respectively.
F-18
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
(10) SEGMENT INFORMATION
Operating and Geographic Segments
The Company operates in a single industry segment: the design, manufacture,
and marketing of x-ray imaging systems. Because of differences in distribution
costs, strategies, and aftermarket potential, the Company separately manages
and reports operating results for products sold by the Company (proprietary)
from those manufactured for sale to other medical products companies under
Original Equipment Manufacturer ("OEM") contracts. The Company's manufacturing
and most distribution activities are in the United States, including export
sales to Europe, primarily, and elsewhere. The Company also has marketing
operations in Europe and Australia. The following is a summary of the
Company's operations by segment (in thousands):
<TABLE>
<CAPTION>
United States International
---------------------------------- ---------------- Internal
Proprietary OEM Export Total Australia Europe Sales Total
----------- ------- ------ ------- --------- ------ -------- -------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
1998:
Revenues:
Product.............. $31,407 $14,604 $4,771 $50,782 $ 475 $520 $(866) $50,911
Service.............. 8,528 -- -- 8,528 173 192 -- 8,893
------- ------- ------ ------- ------ ---- ----- -------
39,935 14,604 4,771 59,310 648 712 (866) 59,804
------- ------- ------ ------- ------ ---- ----- -------
Costs of sales:
Product.............. 17,972 9,531 2,862 30,365 366 295 (866) 30,160
Service.............. 1,671 -- -- 1,671 139 40 -- 1,850
------- ------- ------ ------- ------ ---- ----- -------
Allocated............ 19,643 9,531 2,862 32,036 505 335 (866) 32,010
------- ------- ------
Unallocated.......... 4,873 -- -- -- 4,873
------- ------ ---- ----- -------
36,909 505 335 (866) 36,883
------- ------ ---- ----- -------
Gross profit........... 22,401 143 377 -- 22,921
Operating expenses..... 26,703 520 254 -- 27,477
------- ------ ---- ----- -------
(Loss) income from
operations............ (4,302) (377) 123 -- (4,556)
Interest expense....... (34) (110) (213) -- (357)
Interest income........ 53 15 6 -- 74
Other (expense)
income................ (80) (98) 216 -- 38
Income taxes........... (2,002) -- -- -- (2,002)
------- ------ ---- ----- -------
Net (loss) income...... $(6,365) $ (570) $132 $ -- $(6,803)
======= ====== ==== ===== =======
Identifiable assets.... $49,379 $ 629 $961 $50,969
======= ====== ==== =======
Capital expenditures... $ 1,299 $ -- $-- $ 1,299
======= ====== ==== =======
Depreciation........... $ 2,233 $ 10 $ 28 $ 2,271
======= ====== ==== =======
</TABLE>
F-19
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
<TABLE>
<CAPTION>
United States International
----------------------------------- ---------------- Internal
Proprietary OEM Export Total Australia Europe Sales Total
----------- ------- ------ -------- --------- ------ -------- --------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
1997:
Revenues:
Product.............. $27,927 $17,826 $3,180 $ 48,933 $ 966 $ 409 $ (971) $ 49,337
Service.............. 7,057 -- -- 7,057 197 317 -- 7,571
------- ------- ------ -------- ------ ------ ------- --------
34,984 17,826 3,180 55,990 1,163 726 (971) 56,908
------- ------- ------ -------- ------ ------ ------- --------
Costs of sales:
Product.............. 15,806 11,012 1,963 28,781 732 412 (836) 29,089
Service.............. 1,774 -- -- 1,774 68 110 (135) 1,817
------- ------- ------ -------- ------ ------ ------- --------
Allocated............ 17,580 11,012 1,963 30,555 800 522 (971) 30,906
------- ------- ------
Unallocated.......... 8,346 -- -- -- 8,346
-------- ------ ------ ------- --------
38,901 800 522 (971) 39,252
-------- ------ ------ ------- --------
Gross profit........... 17,089 363 204 -- 17,656
Operating expenses..... 29,196 633 425 -- 30,254
-------- ------ ------ ------- --------
Loss from operations... (12,107) (270) (221) -- (12,598)
Interest expense....... 132 (116) (197) -- (181)
Interest income........ 251 16 4 -- 271
Other expense, net..... (11) (370) (379) -- (760)
Income taxes........... -- -- -- -- --
-------- ------ ------ ------- --------
Net loss............... $(11,735) $ (740) $ (793) $ -- $(13,268)
======== ====== ====== ======= ========
Identifiable assets.... $ 47,647 $ 920 $ 577 $ 49,144
======== ====== ====== ========
Capital expenditures... $ 1,725 $ 3 $ -- $ 1,728
======== ====== ====== ========
Depreciation........... $ 1,957 $ 9 $ 15 $ 1,981
======== ====== ====== ========
1996:
Revenues:
Product.............. $32,199 $31,422 $5,633 $ 69,254 $2,641 $2,329 $(4,123) $ 70,101
Service.............. 6,998 -- -- 6,998 257 152 -- 7,407
------- ------- ------ -------- ------ ------ ------- --------
39,197 31,422 5,633 76,252 2,898 2,481 (4,123) 77,508
------- ------- ------ -------- ------ ------ ------- --------
Costs of sales:
Product.............. 17,914 20,252 3,970 42,136 2,152 1,897 (3,962) 42,223
Service.............. 1,660 -- -- 1,660 112 98 (61) 1,809
------- ------- ------ -------- ------ ------ ------- --------
Allocated............ 19,574 20,252 3,970 43,796 2,264 1,995 (4,023) 44,032
------- ------- ------
Unallocated.......... 3,041 -- -- -- 3,041
-------- ------ ------ ------- --------
46,837 2,264 1,995 (4,023) 47,073
-------- ------ ------ ------- --------
Gross profit........... 29,415 634 486 (100) 30,435
Operating expenses..... 28,574 756 1,055 -- 30,385
-------- ------ ------ ------- --------
Income (loss) from
operations............ 841 (122) (569) (100) 50
Interest expense....... (344) (89) (162) -- (595)
Interest income........ 113 21 4 -- 138
Other income
(expense)............. 3 61 (227) -- (163)
Income tax benefit..... 209 -- -- -- 209
-------- ------ ------ ------- --------
Net income (loss)...... $ 822 $ (129) $ (954) $ (100) $ (361)
======== ====== ====== ======= ========
Identifiable assets.... $ 57,054 $1,797 $1,581 $ 60,432
======== ====== ====== ========
Capital expenditures... $ 2,265 $ 35 $ -- $ 2,300
======== ====== ====== ========
Depreciation........... $ 1,567 $ 42 $ 20 $ 1,629
======== ====== ====== ========
</TABLE>
F-20
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Internal sales from the United States to Australia and Europe are recorded
on the basis of transfer pricing established by the Company. International
sales to OEM customers are managed and, therefore, reported as part of OEM
business results.
Significant Customers
The Company's revenues generally are concentrated among customers in the
healthcare industry and from customers under Original Equipment Manufacturer
("OEM") contracts. The Company establishes an allowance for uncollectible
accounts based upon factors surrounding the credit risk of specific customers,
historical trends, and other information.
During 1998, 1997, and 1996, the following customers represented greater
than 5% of the Company's revenues:
<TABLE>
<CAPTION>
1998 1997 1996
---- ---- -----
<S> <C> <C> <C>
Proprietary products:
Diagnostic Imaging (dealer)............................. 6.7% -- % -- %
OEM products:
Dornier................................................. -- -- 7.0
GE Medical Systems (a related party).................... 5.9 7.5 12.9
International Surgical Systems.......................... 7.9 5.0 --
Picker International.................................... 7.9 -- --
Storz Medical........................................... -- 5.3 --
Varian Associates....................................... -- 5.5 8.4
</TABLE>
The OEM customers are medical products companies for whom the Company
manufactures sub-components and systems under OEM contracts. Sales under OEM
contracts constitute a substantial portion of the Company's revenues and trade
accounts receivable. As of December 31, 1998 and 1997, amounts owed the
Company under OEM contracts were approximately $3.4 million and $4.7 million,
respectively. Revenues from OEM customers, which can fluctuate significantly,
represented 24%, 31%, and 41% of the Company's revenue in 1998, 1997, and
1996, respectively. There is no assurance that OEM arrangements will be
renewed upon expiration nor, generally, are minimum order quantities specified
in these agreements.
(11) COMMITMENTS AND CONTINGENCIES
Litigation Reserve
The Company is party to a lawsuit, as guarantor of work performed by a now-
bankrupt dealer in the United Kingdom. Damages and legal fees totaling
approximately $1.5 million are being sought for allegedly deficient pre-
installation site review and installation work. The trial ended February 25,
1999. It is expected that a judgement will be rendered by early April 1999.
Based on a review of the evidence and testimony presented at trial, management
believes that a loss contingency reserve of $0.5 million is warranted.
Other Litigation
The Company is involved in other miscellaneous litigation arising in the
ordinary course of business. Management believes the resolution of these
contingencies will not have a material adverse impact on the Company's
operations or financial position.
F-21
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Operating Leases
The Company leases buildings (see Note 9) and equipment under various
operating lease agreements which provide for the following minimum future
lease payments (in thousands):
<TABLE>
<S> <C>
1999............................................................. $ 907
2000............................................................. 823
2001............................................................. 765
2002............................................................. 744
2003............................................................. 744
Thereafter....................................................... 6,386
-------
Total.......................................................... $10,369
=======
</TABLE>
In January 1999, the Company negotiated a buyout of its obligations under a
lease commitment for its Addison, Illinois manufacturing facility and,
accordingly, such commitments are excluded from the amounts listed above (See
Note 6).
Total rent expense was $1.6 million, $1.9 million and $1.8 million in 1998,
1997, and 1996, respectively.
Regulatory Actions
The Company's Denver facility is subject to periodic inspections by the Food
and Drug Administration ("FDA") whose primary purpose is to audit the
Company's compliance with Good Manufacturing Practices ("GMPs"), which include
testing, quality control and documentation procedures.
In March 1995, the Company was issued a Warning Letter concerning
documentation and other deficiencies. The Company rectified these deficiencies
and resolved the matter with the FDA later that year.
Following an inspection which concluded in late 1996, the FDA issued
Inspectional Observations Form 483 ("Form 483") and Warning Letter concerning
deficiencies in manufacturing practices. The FDA requested and subsequently
received a written response to the Warning Letter regarding the Company's
planned corrective actions and a favorable third-party certification of the
Company's manufacturing and quality systems.
In October 1998, following a periodic inspection, the FDA issued a Form 483
regarding possible deficiencies in manufacturing, quality, and documentation
practices. The Company has responded to the Form 483 and is presently
instituting corrective actions.
Failure to satisfy FDA requirements can result in the Company's inability to
receive awards of federal government contracts, to receive new marketing or
export clearance for products manufactured at its Denver facility, or FDA
enforcement actions including, among other things, product seizure,
injunction, and/or criminal or civil proceedings being initiated without
further notice. The recent issuance of another Form 483 increases the
possibility that one or more of these sanctions could be imposed in the
future.
Although the Company strives to operate within the requirements imposed by
the FDA, there can be no assurances that these deficiencies can be corrected
or that the Company will be able to satisfy FDA compliance concerns in the
future. Ongoing compliance reviews and/or related delays in product clearances
could have a material adverse effect on the Company.
F-22
<PAGE>
FISCHER IMAGING CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
Purchase Commitments
The Company has entered into an agreement with a vendor for the development
and production of certain components to be used in one of the Company's new
products. In order to retain exclusive rights to the technology developed, the
Company must order a minimum quantity of units or pay approximately $680,000.
Should the minimum quantity be ordered, the total commitment through 1999
would approximate $7.2 million.
In the normal course of business, the Company enters into various long-term
commitments with vendors to provide customized materials for use in the
Company's products.
Retention Bonus Plan
In December 1995, the Board of Directors adopted a Retention Bonus Plan (the
"Plan"). Under the Plan, the Company will vest all options to purchase shares
of Common Stock and will make payments to executive officers and other key
employees of the Company (the "Participants") in the event of a change of
control of the Company. A "change of control" under the Plan is defined to
include acquisition of 35% or more of the Company's outstanding Common Stock,
certain changes in the composition of the Board of Directors, a consolidation
or merger in which the Company is not the surviving corporation, the sale or
other transfer of 50% or more of the assets or earnings power of the Company,
the adoption of a plan of liquidation or dissolution of the Company, or
certain other similar events. Payments made to a Participant under the Plan
will not exceed an amount equal to his or her annual base salary in effect
immediately prior to the change of control. Current participants, including
all executive officers of the Company, were selected by the Board of
Directors, who may select additional Participants in the future.
Anti-Takeover Contingencies
In November 1994, the Board of Directors declared a dividend of one right to
purchase a share of Series C Junior Participating Preferred Stock for each
outstanding share of common stock. These rights generally become exercisable
when anyone other than certain exempt persons (including Morgan W. Nields,
Chairman and Chief Executive Officer, Kinney L. Johnson, member of the Board
of Directors, and GE Medical Systems) acquire more than a 15% beneficial
interest in the Company. The purpose of these rights is to assure that the
Company's Board of Directors has sufficient control to prevent a takeover of
the Company at less than its fair value.
F-23
<PAGE>
LIST OF SUBSIDIARIES
1. Fischer Imaging Europe A/S
2. Fischer Imaging Australia Pty. Ltd.
3. Fischer Imaging (China Limited)
4. Fischer Export Limited
5. Bloom Associates Ltd.
<PAGE>
EXHIBIT 23
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the use of our reports
and to all references to our Firm included in or made part of this Form 10-K and
to the incorporation by reference of our reports included in this Form 10-K into
the Company's previously filed Registration Statements on Form S-8 (File Nos.
33-44012, 33-44599, 33-64032, 333-2676 and 333-70057).
/s/ Arthur Andersen LLP
Denver, Colorado
March 30, 1999
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-END> DEC-31-1998
<CASH> 929
<SECURITIES> 0
<RECEIVABLES> 17,523
<ALLOWANCES> 726
<INVENTORY> 22,023
<CURRENT-ASSETS> 40,847
<PP&E> 15,403
<DEPRECIATION> 9,994
<TOTAL-ASSETS> 50,969
<CURRENT-LIABILITIES> 21,752
<BONDS> 587
0
13
<COMMON> 70
<OTHER-SE> 28,347
<TOTAL-LIABILITY-AND-EQUITY> 50,969
<SALES> 59,804
<TOTAL-REVENUES> 59,804
<CGS> 36,883
<TOTAL-COSTS> 36,883
<OTHER-EXPENSES> 27,477
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 357
<INCOME-PRETAX> (4,801)
<INCOME-TAX> 2,002
<INCOME-CONTINUING> (6,803)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (6,803)
<EPS-PRIMARY> (0.97)
<EPS-DILUTED> (0.97)
</TABLE>
